Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 2277. Отображено 100.
02-02-2012 дата публикации

Heterocycle-amino acid derivatives for targeting cancer tissue and radioactive or non-radioactive labeled compounds thereof

Номер: US20120029177A1
Принадлежит: SNU R&DB FOUNDATION

The present invention relates to novel amino acid derivatives containing heterocyclic chelating residues thereof; radioactive or nonradioactive metal complexes thereof; methods for preparation thereof; and apyrogenic and sterile preparative kits of the composition for targeting cancer cells. The compounds of the present invention can easily be taken up to cancer cells as they contain amino acid residues thereof; radioactive or nonradioactive metals can be labeled easily as they contain heterocyclic chelating residues thereof; cancer lesion can be imaged easily by targeting using the present invention.

Подробнее
03-05-2012 дата публикации

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20120108062A1
Принадлежит: Applied Materials Inc

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands.

Подробнее
16-08-2012 дата публикации

Cancer-imaging agent and method of radioimaging using the same

Номер: US20120207674A1
Принадлежит: University of Kuwait

The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99m TcO 4 , which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.

Подробнее
23-08-2012 дата публикации

Preparation of metal-catecholate frameworks

Номер: US20120215015A1
Принадлежит: UNIVERSITY OF CALIFORNIA

The disclosure provides for metal catecholate frameworks, and methods of use thereof, including gas separation, gas storage, catalysis, tunable conductors, supercapacitors, and sensors.

Подробнее
18-10-2012 дата публикации

Substituted porphyrins

Номер: US20120264725A1
Принадлежит: Individual

Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described.

Подробнее
25-10-2012 дата публикации

Heterodimers of Glutamic Acid

Номер: US20120269726A1
Принадлежит: Molecular Insight Pharmaceuticals Inc

Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Y is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH2)p Z is H or C 1 -C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 1 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

Подробнее
13-06-2013 дата публикации

IMAGING TUBERCULOSIS WITH PYRAZINAMIDE CONTRAST AGENTS

Номер: US20130149249A1
Принадлежит: GE HEALTHCARE LIMITED

The present invention provides novel in vivo imaging agents useful for detecting the presence of mycobacteria using in vivo imaging methods. Also provided by the present invention is a precursor compound useful in the synthesis of the in vivo imaging agents of the invention, and a method to obtain the in vivo imaging agent of the invention using said precursor compound. Methods of in vivo imaging and diagnosis in which the in vivo imaging agent of the invention finds use are also provided. 2) The in vivo imaging agent as defined in wherein said metal ion suitable for in vivo imaging is either a radioactive metal ion or a paramagnetic metal ion.3) The in vivo imaging agent as defined in wherein said radioactive metal ion is a gamma-emitting radioactive metal ion selected from Tc claim 2 , In claim 2 , In claim 2 , and Ga.4) The in vivo imaging agent as defined in wherein said radioactive metal ion is Tc.5) The in vivo imaging agent as defined in wherein said radioactive metal ion is a positron-emitting radioactive metal ion selected from Cu claim 2 , V claim 2 , Fe claim 2 , Co claim 2 , Tc and Ga.6) The in vivo imaging agent as defined in wherein said paramagnetic metal ion is selected from Gd(III) claim 2 , Mn(II) claim 2 , Cu(II) claim 2 , Cr(III) claim 2 , Fe(III) claim 2 , Co(II) claim 2 , Er(II) claim 2 , Ni(II) claim 2 , Eu(III) and Dy(III).7) The in vivo imaging agent as defined in wherein Chis:(a) diaminedioximes;{'sub': '3', '(b) NS ligands having a thioltriamide donor set;'}{'sub': 2', '2, '(c) NSligands having a diaminedithiol donor set;'}{'sub': '4', '(d) Nligands which are open chain or macrocyclic ligands having a tetramine, amidetriamine or diamidediamine donor set; or,'}{'sub': 2', '2, '(e) NOligands having a diaminediphenol donor set.'}8) A pharmaceutical composition comprising the in vivo imaging agent as defined in together with a pharmaceutically acceptable carrier.11) The method as defined in wherein said source of metal ion suitable for in vivo ...

Подробнее
20-06-2013 дата публикации

Rhenium complexes and their pharmaceutical use

Номер: US20130158109A1

The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R′ is a phenyl group or a group of general Formula —(CH 2 ) q —COOH wherein q=1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).

Подробнее
27-06-2013 дата публикации

Thermally stable volatile precursors

Номер: US20130164456A1
Принадлежит: WAYNE STATE UNIVERSITY

A method of forming a thin film on a substrate which includes a step of contacting a surface with a precursor compound having a transition metal and one or more alkyl-1,3-diazabutadiene ligands is provided. The resulting modified surface is then contacted with an activating compound.

Подробнее
04-07-2013 дата публикации

TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS

Номер: US20130171067A1
Принадлежит: Pierre Fabre Medicament SA

The invention relates to a compound having formula (I), compositions containing same and preparation methods thereof. The invention also relates to a complex of the compound having formula (I) with technetium-99m and tricine, the use of this complex as a diagnostic probe, diagnostic compositions containing same and methods for preparing the complex and compositions containing same.

Подробнее
18-07-2013 дата публикации

HETEROCYCLIC MACROCYCLE TEMPLATED METAL-ORGANIC MATERIALS

Номер: US20130184456A1
Принадлежит: UNIVERSITY OF SOUTH FLORIDA

A process for the preparation of a heterocyclic macrocycle-templated supramolecular metal organic material, the process comprising preparing a reaction mixture containing a metal, a heterocyclic macrocycle, and organic ligands and forming, in the reaction mixture, a heterocyclic macrocycle-templated metal organic material comprising the metal, the heterocyclic macrocycle and the ligands by template-directed synthesis with the heterocyclic macrocycle serving as the template and being encapsulated within a cage of the template metal organic material. 1. A process for the preparation of a heterocyclic macrocycle-templated supramolecular metal organic material , the process comprising preparing a mixture containing a metal , a heterocyclic macrocycle , and organic ligands and forming , in the mixture , a heterocyclic macrocycle-templated metal organic material comprising the metal , the heterocyclic macrocycle and the ligands by template-directed synthesis with the heterocyclic macrocycle serving as the template.2. The process of wherein the heterocyclic macrocycle is a porphyrin claim 1 , a porphyrazin claim 1 , a chlorin claim 1 , a corrin claim 1 , or a porphyrinogen.3. The process of wherein the heterocyclic macrocycle is a metalated porphyrin claim 1 , a metalated porphyrazin claim 1 , a metalated chlorin claim 1 , a metalated corrin claim 1 , or a metalated porphyrinogen.4. The process of wherein the heterocyclic macrocycle is a metalated porphyrin claim 1 , a metalated porphyrazin claim 1 , a metalated chlorin claim 1 , a metalated corrin claim 1 , or a metalated porphyrinogen and the metal coordinated by the metalated porphyrin claim 1 , metalated porphyrazin claim 1 , metalated chlorin claim 1 , metalated corrin claim 1 , or metalated porphyrinogen is Sc claim 1 , Ti claim 1 , V claim 1 , Cr claim 1 , Mn claim 1 , Fe claim 1 , Co claim 1 , Ni claim 1 , Cu claim 1 , Zn claim 1 , Y claim 1 , Zr claim 1 , Nb claim 1 , Mo claim 1 , Tc claim 1 , Ru claim 1 , Rh ...

Подробнее
22-08-2013 дата публикации

METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX

Номер: US20130216477A1
Принадлежит: Molecular Insight Pharmaceuticals

The present invention is directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. 2. The compound of claim 1 , in which X is —(CH)— and m is 2.3. The compound of claim 1 , in which X is O— and m is 4.4. The compound of claim 1 , in which Rand Rare each independently carboxy(C-C)alkylene claim 1 , Ris hydrogen and Ris (C-C)alkyl.6. The compound of claim 1 , in which Rand Rare each independently hydrogen claim 1 , and Rand R(C-C)alkyl.8. The compound of claim 1 , in which the compound is an inhibitor of carbonic anhydrase (CA) IX.11. The metal complex of claim 10 , in which the metal is Tc claim 10 , Re claim 10 , or Re.13. The metal complex of claim 10 , in which the ratio of the sum of percent injected dose per gram tissue (% ID/g) values for liver and kidney tissues to the % ID/g value for tumor tissue decreases when observed at a first time point claim 10 , which is one hour post-administration of the metal complex to CA9/293 xenograft mice claim 10 , and at a second time point claim 10 , which is four hours post-administration of the metal complex to CA9/293 xenograft mice.14. The metal complex of claim 13 , in which the decrease in the ratio ranges from about a factor of about 2 to a factor of about 4.15. A pharmaceutical composition comprising at least one compound of Formula I claim 13 , or a pharmaceutically acceptable salt claim 13 , tautomer claim 13 , or ester thereof; and a pharmaceutically acceptable carrier.16. A pharmaceutical composition comprising at least one metal complex of a compound of Formula I claim 13 , or a pharmaceutically acceptable salt claim 13 , tautomer claim 13 , or ester thereof; and a pharmaceutically acceptable carrier.17. A method for imaging a patient suspected of harboring CA IX expressing tumor tissue claim 13 , comprising:(a) administering to a patient suspected of harboring CA IX expressing tumor tissue a diagnostically effective amount of a radionuclide metal ...

Подробнее
29-08-2013 дата публикации

ENHANCED BIOAVAILABLE IODINE MOLECULES

Номер: US20130225847A1
Автор: Stark Peter A.
Принадлежит: ZINPRO CORPORATION

This invention relates to supplementation of the diets of domesticated animals (livestock and poultry) with iodine in an enhanced bioavailable manner, that is to say the iodine is more available to the animal than when using conventional sources of iodine, such as calcium iodate. The supplementary compound are alpha amino acid metal iodide complexes. 2. The compound of wherein M is zinc.3. The compound of wherein M is manganese.4. The compound of wherein M is iron. This application is a divisional application of U.S. Ser. No. 13/037,716 filed Mar. 1, 2011, herein incorporated by reference in its entirety.This invention relates to supplementation of the diets of domesticated animals (livestock and poultry) with iodine in an enhanced bioavailable manner, that is to say the iodine is more available to the animal than when using conventional sources of iodine, such as calcium iodate. The supplementary compound are alpha amino acid metal iodide complexes.It is well known that domesticated animals (livestock and poultry) are in need of bioavailable metal or mineral supplements, essential amino acids, and also are in need of iodine for healthy animal nutrition.Iodine is a key component of hormones produced by the thyroid gland. The thyroid is responsible for growth, brain development and the rate at which animals burn energy. Two of the most common sources of iodine used in animal nutrition and therefore used in supplementing animal diets are calcium iodate (CaI0) and ethylenediamine dihydoiodide (EDDI). One test of the efficiency of effective metabolization of the iodine source by an animal is measuring blood serum levels of iodine after ingesting of the nutrient material.In the animal feed industry it is known that insufficient availability of iodine to the animal can result in conditions such as goiters, reproductive failure, weak offspring, reduced milk yield, mastitis, abnormal respiration, reduced growth rate and even hairless offspring. The traditional toxicity ...

Подробнее
05-09-2013 дата публикации

Enhanced bioavailable iodine molecules

Номер: US20130230619A1
Автор: Peter A. Stark
Принадлежит: Zinpro Corp

This invention relates to supplementation of the diets of domesticated animals (livestock and poultry) with iodine in an enhanced bioavailable manner, that is to say the iodine is more available to the animal than when using conventional sources of iodine, such as calcium iodate. The supplementary compound are alpha amino acid metal iodide complexes.

Подробнее
26-09-2013 дата публикации

Diazadiene-based metal compound, method for preparing same and method for forming a thin film using same

Номер: US20130251903A1
Автор: Won Seok Han
Принадлежит: UP Chemical Co Ltd

The present invention relates to a diazadiene (DAD)-based metal compound, to a method for preparing the same and to a method for forming a thin film using the same. The diazadiene (DAD)-based metal compound of the present invention is provided in a gaseous state to be formed into a metal thin film or a metal oxide thin film by chemical vapor deposition or atomic layer deposition. Particularly, the diazadiene-based organic metal compound of the present invention has advantages in that it may be formed into a metal thin film or a metal oxide thin film and it can be prepared in a relatively inexpensive way without using highly toxic ligands.

Подробнее
10-10-2013 дата публикации

BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS

Номер: US20130267714A1
Принадлежит:

Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers, 1. Compounds of the formula (I) in the form of a mixture of predominantly one diastereomer or in the form of pure diastereomers ,{'br': None, 'sub': 1', '0', '1, 'Z-Q-P*RR\u2003\u2003(I),'}wherein:{'sub': 1', '2, 'claim-text': {'sub': 1', '6', '1', '6', '1', '4', '2', '6', '5', '3', '1', '12', '3, 'wherein R is a hydrocarbon radical or O-atom(s)-containing heterohydrocarbon radical having 1 to 18 carbon atoms and optionally substituted by C-C-alkyl, trifluoromethyl, C-C-alkoxy, trifluoromethoxy, (C-C-alkyl)amino, (CH)Si, (C-C-alkyl)Si or halogen;'}, 'Zis a C-bonded, secondary phosphine group of the formula —P(R),'} [{'sub': 1', '0', '1, '(i) an optionally substituted achiral aromatic group, wherein the achiral aromatic group is bonded directly to Zthrough a carbon atom of the achiral aromatic group and bonded directly to P*RRthrough a carbon atom of the achiral aromatic group, and'}, {'sub': 1', '4, '(ii) an optionally substituted C-C-alkylene group;'}], 'Q is selected from the group consisting ofP* is a chiral phosphorus atom;{'sub': '0', 'Ris methyl; and'}{'sub': '1', 'Ris a C-bonded optically enriched or optically pure chiral, mono- or polycyclic, nonaromatic hydrocarbon ring.'}23-. (canceled)4. The compounds according to claim 1 , wherein the secondary phosphine Zis selected from the group consisting of: —P(C-C-alkyl) claim 1 , —P(C-C-cycloalkyl) claim 1 , —P(o-furyl) claim 1 , —P(CH) claim 1 , —P[2-(C-C-alkyl)CH] claim 1 , —P[3-(C-C-alkyl)CH] claim 1 , —P[4-(C-C-alkyl)CH] claim 1 , —P[2-(C-C-alkoxy)CH] claim 1 , —P[3-(C-C-alkoxy)CH] claim 1 , —P[4-(C-C-alkoxy)CH] claim 1 , —P[2-(trifluoromethyl)CH] claim 1 , —P[3-(trifluoromethyl)CH] claim 1 , —P[4-(trifluoromethyl)CH] claim 1 , —P[3 claim 1 ,5-bis(trifluoromethyl)CH] claim 1 , —P[3 claim 1 ,5-bis(C-C-alkyl)CH] claim 1 , —P[3 claim 1 ,5-bis(C-C-alkoxy)CH]and —P[3 claim 1 ,5-bis(C-C-alkyl ...

Подробнее
17-10-2013 дата публикации

(AMIDE AMINO ALKANE) METAL COMPOUND, METHOD OF MANUFACTURING METAL-CONTAINING THIN FILM USING SAID METAL COMPOUND

Номер: US20130273250A1
Принадлежит: UBE INDUSTRIES, LTD

The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): 2. The (amide amino alkane) metal compound as claimed in claim 1 , wherein M is sodium claim 1 , magnesium claim 1 , manganese claim 1 , iron claim 1 , cobalt claim 1 , nickel claim 1 , zinc claim 1 , yttrium claim 1 , lanthanum claim 1 , or indium.7. A method of producing a metal-containing thin film by a chemical vapor deposition method claim 1 , wherein an (amide amino alkane) metal compound as claimed in is used as a source.8. A material for forming a metal-containing thin film claim 1 , comprising an (amide amino alkane) metal compound as claimed in . The present invention relates to a novel (amide amino alkane) metal compound, and a method of producing a metal-containing thin film on an object by a chemical vapor deposition method (hereinafter, referred to as CVD method) using the metal compound.In recent years, various metal-containing thin films have been researched and developed as materials in the field of semiconductors, electronic components, and the like.Conventionally, various magnesium compounds such as bis(cyclopentadienyl)magnesium, magnesium alkoxide and magnesium diketonato, for example, have been known as magnesium compounds to be used for the formation of magnesium-containing thin film (See Patent Documents 1 to 2). Among them, bis(cyclopentadienyl)magnesium, and analogs thereof are relatively frequently employed. Meanwhile, bis(amide amino alkane) magnesium compounds have been known and used as a catalyst, and a material for the production of medicines, agricultural chemicals, and the like, for example (See Non-Patent Documents 1 to 2).There have been proposed, as cobalt compounds to be used for the formation of thin film, bis(acetylacetonato)cobalt (See, for example, Non-Patent Document 3), bis(dipivaloylmethanato)cobalt (See, for example, Non-Patent Document 4), octacarbonyl dicobalt (See, for example, Non-Patent Document 5 and Patent ...

Подробнее
31-10-2013 дата публикации

IONIC FLUIDS

Номер: US20130288886A1
Принадлежит: RELIANCE INDUSTRIES LTD.

A method for preparing an ionic compound by mixing at least one compound of formula CA-zHO (1) with at least one hydrogen donor and heating the mixture obtained is provided. The said ionic compound remains in a physical state selected from the group consisting of liquid and semisolid at a temperature below 150° C., preferably below 125° C. 19.-. (canceled)10. A process for preparation of an ionic compound that remains in a physical state selected from the group consisting of liquid and semisolid , at a temperature below 150° C. , preferably below 125° C. , comprising mixing at least one compound of Formula CA.zHO (I) with at least one hydrogen donor and heating the resulting mixture to obtain an ionic compound;wherein, C is independently selected from the group consisting of Na, K, Li, Mg, Ca, Cr, Mn, Fe, Co, Mo, Ni, Cu, Zn, Cd, Sn, Pb, St, Bi, La, Ce, Al, Hg, Cs, Rb, Sr, V, Pd, Zr, Au, Pt, quaternary ammonium, immidazolium, phosphonium, and pyridinium, pyrrolidinium;{'sub': 3', '4', '3', '2', '4, 'A is independently selected from the group consisting of Cl, Br, F, I, NO, SO, CHCOO, HCOO and CO; and'}z is 0 to 20.11. The process as claimed in claim 10 , wherein the hydrogen donor is at least one selected from the group consisting of toluene-4-sulphonic acid monohydrate claim 10 , oxalic acid claim 10 , maleic acid claim 10 , citric acid and methane sulfonic acid.12. The process as claimed in claim 10 , wherein the mixture is heated to up to 150° C.13. A process as claimed in claim 10 , further comprising the method step of dissolving the ionic compound in at least one solvent selected from the group consisting of carboxylic acids claim 10 , amides claim 10 , alcohols claim 10 , amines claim 10 , ketones (aldehydes) claim 10 , esters claim 10 , alkyl halides claim 10 , ethers claim 10 , aromatics for example; methanol claim 10 , ethanol claim 10 , propan-1-ol claim 10 , propan-2-ol claim 10 , 1-butanol claim 10 , isobutanol claim 10 , 2-butanol claim 10 , tert- ...

Подробнее
09-01-2014 дата публикации

PEPTIDOMIMETIC INHIBITORS OF PSMA

Номер: US20140010758A1
Принадлежит:

Compounds of the formulae, (I), wherein each variable is as defined herein are provided which are useful in (i) diagnostic methods for detecting and/or identifying cells presenting PSMA; (2) compositions comprising a compound of the invention together with a pharmaceutically acceptable carrier, excipient, and/or diluent; (3) methods for inhibiting or treating prostrate cancer; and (4) methods for blocking or destabilizing neovasculature of a tumor. 2. The compound of claim 1 , wherein Ris —C(H)(COOR)N(H)C(O)(C-C)alkyl-R claim 1 , —C(H)(COOR)N(H)C(O)hetero aryl-R claim 1 , —C(H)(COOR)N(H)C(O)-G-CHCH—R claim 1 , —C(H)(COOR)N(H)C(O)(C-C)alkyl-O—(C-C)alkyl-R claim 1 , or —R.4. The compound of claim 1 , wherein Rand Rare each —C(O)OH.5. The compound of claim 1 , wherein Ris —C(O)OH.6. The compound of claim 1 , wherein R claim 1 , R claim 1 , and Rare each benzyloxycarbonyl.9. The compound of claim 7 , wherein each Ris benzyl.10. The compound of claim 7 , wherein each Ris hydrogen.11. The compound of claim 1 , wherein Ris a detectable label.12. The compound of claim 11 , wherein Ris F.13. The compound of claim 12 , wherein Ris a chelated Tc claim 12 ,Cu claim 12 , Ga claim 12 , or In.14. The compound of claim 12 , wherein Ris Tc coordinated to a chelating moiety.15. The compound of claim 1 , wherein Ris a pendant group comprising either a detectable label claim 1 , or a cytotoxic group.16. The compound of claim 15 , wherein Ris a pendant group comprising F.17. The compound of claim 16 , wherein Ris a pendant group comprising a cytotoxic group claim 16 , and the cytotoxic group is paclitaxel or doxorubicin.2019. A composition comprising a compound of any one of - together with a pharmaceutically acceptable carrier claims 1 , excipient claims 1 , and/or diluent.2119. A method for detecting and/or identifying cells presenting PSMA comprising contacting a cell suspected of presenting PSMA with a compound of any one of - or a composition of .2219. A method for inhibiting or ...

Подробнее
06-02-2014 дата публикации

Method for Producing Amino Acid Chelate Compounds, Amino Acid Chelate Compounds and Use of Amino Acid Chelate Compounds

Номер: US20140037960A1
Принадлежит: ISF GMBH

A method for producing amino acid chelate compounds, characterized in that metal oxides and/or metal carbonates and/or metal sulfates and/or metal chlorides and/or metal hydroxides in solid form are activated mechanically and then the activated metal oxides and/or metal carbonates and/or metal hydroxides and/or metal sulfates and/or metal chlorides are brought together with amino acids in solid form and converted to amino acid chelate compounds in a solid-state reaction. 1. A method for producing amino acid chelate compounds , whereinmetal oxides and/or metal carbonates and/or metal sulfates and/or metal chlorides and/or metal hydroxides in solid form are activated mechanically and then the activated metal oxides and/or metal carbonates and/or metal hydroxides and/or metal sulfates and/or metal chlorides are brought together with amino acids in solid form and converted to amino acid chelate compounds in a solid-state reaction.2. The method according to claim 1 , in which at least one reactant is thermally activated.3. The method according to claim 2 , in which the thermal activation takes place at the same time as the mechanical activation and/or in which the thermal activation takes place at the same time as the conversion.4. The method according to claim 1 , in which water created during the conversion is separated from the reactants.5. The method according to claim 4 , in which the water is separated by evaporation from the reactants.6. The method according to claim 1 , in which the raw materials are added dry.7. The method according to claim 1 , in which the metal compounds are added as a mixture of loose particles and/or amino acids as a mixture of loose particles.8. The method according to claim 1 , in which the activation and the conversion are executed in the same reactor.9. The method according to claim 1 , in which the activation and the conversion are executed in different reactors.10. The method according to claim 1 , in which the activation and/or the ...

Подробнее
13-02-2014 дата публикации

POLYNUCLEAR METAL CLUSTERS, METHODS OF MAKING, AND METHODS OF USE THEREOF

Номер: US20140042035A1
Принадлежит:

Embodiments of the present disclosure provide for polynuclear manganese cluster compounds, methods of making, methods of use, method of producing hydrogen and oxygen from water, and the like. 1. A composition , comprising a polynuclear manganese cluster compound having oxygen-containing groups , wherein each oxygen-containing group is independently selected from the group consisting of: a carboxylate group , an alcohol group , an alkoxide group , an ether group , and a combination thereof.2. The composition of claim 1 , comprising a polynuclear manganese cluster compound having the formula MnMR claim 1 , wherein R is an oxygen containing ligand claim 1 , M is Ca claim 1 , Sr claim 1 , or Ce claim 1 , x can be 2 to 84 claim 1 , y can be 0 to 2 claim 1 , and z can be 8 to 24.3. The composition of claim 1 , comprising a polynuclear manganese cluster compound having a formula selected from one of the following: MnO(OCR)(HO) claim 1 , MnO(R)(HO) claim 1 , MnCaO(R)(HO) claim 1 , MnSrO(R)(HO) claim 1 , MnCaO(R)(HO) claim 1 , MnCeO(R)(HO) claim 1 , and MnCeO(R)(HO)where each R is a oxygen-containing group and a is 1 to 6.4. The composition of claim 2 , wherein R is selected from OCCH(OH) claim 2 , OCCHO claim 2 , or OCCHO.5. The composition of claim 1 , wherein the compound is dissolved in an aqueous solution.6. The composition of claim 1 , wherein the polynuclear manganese cluster compound includes 2 claim 1 , 3 claim 1 , 4 claim 1 , 6 claim 1 , 8 claim 1 , 12 claim 1 , 13 claim 1 , and 14 claim 1 , to 84 manganese atoms.7. The composition of claim 1 , wherein the carboxylate group is selected from the group consisting of: OCCH(OH) claim 1 , where q is 2 to 5 claim 1 , OCCHO claim 1 , and OCCHO.8. The composition of claim 1 , wherein the alcohol group is represented by X(X′)(X″)—C—OH claim 1 , wherein X claim 1 , X′ claim 1 , and X″ are independently selected from the group consisting of: a substituted or unsubstituted alkyl group claim 1 , a substituted or unsubstituted ...

Подробнее
20-03-2014 дата публикации

SUBSTITUTED PORPHYRINS

Номер: US20140080797A1
Принадлежит: Duke University

Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described. 2. The compound according to wherein at least one A is halogen claim 1 , NOor CHO.3. The compound according to wherein said compound is of Formula I claim 1 , III claim 1 , V or VII and M is manganese4. The compound according to where said compound is of Formula V claim 1 , VI claim 1 , VII or VIII.5. A method of protecting cells from oxidant-induced toxicity comprising treating said cells with a protective amount of the compound of under conditions such that the protection is effected.6. The method according to wherein said cells are mammalian cells.7. A method of treating a pathological condition of a patient resulting from oxidant-induced toxicity comprising administering to said patient an effective amount of the compound of under conditions such that the treatment is effected.8. A method of treating a pathological condition of a patient resulting from degradation of NO. comprising administering to said patient an effective amount of the compound of under conditions such that the treatment is effected.9. A method of treating a patient for inflammatory lung disease comprising administering to said patient an effective amount of the compound of under conditions such that the treatment is effected.10. A method of treating a neurodegenerative condition of a patient comprising administering to the patient an effective amount of the compound of .11. A method of treating radiation injury and cancer of a patient comprising administering to the patient an effective amount of the compound of .12. A method of treating a diabetic ...

Подробнее
27-03-2014 дата публикации

ZEOLITE POROUS METAL BIS(IMIDAZOLE) COORDINATION POLYMERS AND PREPARATION METHOD THEREOF

Номер: US20140088312A1
Автор: Li Dan, Liu Jie, ZHOU XIAOPING
Принадлежит:

The present invention discloses zeolite metal bis(imidazole) coordination polymers and preparation method thereof. The new class of zeolite coordination polymers of the present invention is a chemical compound with the following general chemical formula {[M(Blm)]×xDMF×yCHO×zHO}, in which when M=Zn, x=0.9, y=0, z=0; when M=Cu, x=1.2, y=0, z=0; when M=Mn, x=2.0, y=0, z=0; when M=Ni, x=0.4, y=1.2, z=1.0, Blm is 1,2-bis((5H-imidazol-4-yl)methylene)hydrazine, DMF is N,N-dimethyl formamide, HO is water. A solvothermal method or slow diffusion is used on the compounds to obtain crystals of high purity. The coordination polymers of the present invention have good thermal stability, and have strong adsorption performance for COunder conditions of 0° C. and normal pressure as adsorbent materials. 1. Zeolite porous metal bis(imidazole) coordination polymer having the following general chemical formula:{'br': None, 'i': x', 'y', 'z, 'sub': 2', '6', '2', '∞, '{[M(Blm)]×DMF×CHO×HO}, whereinM=Zn, x=0.9, y=0, z=0;M=Cu, x=1.2, y=0, z=0;M=Mn, x=2.0, y=0, z=0;M=Ni, x=0.4, y=1.2, z=1.0Blm is 1,2-bis((5H-imidazol-4-yl)methylene)hydrazine, DMF is N,N-dimethyl formamide.2. The porous coordination polymers according to claim 1 , wherein crystals of the zeolite porous metal bis(imidazole) coordination polymers belong to a cubic system claim 1 , space group is Ia d claim 1 , and cell parameter are:{'sup': '3', 'zinc 1,2-bis((5H-imidazol-4-yl)methylene)hydrazine: a=b=c=34.6471(2) Å, α=β=γ90°, V=41591.1(4) Å;'}{'sup': '3', 'copper-1,2-bis((5H-imidazol-4-yl)methylene)hydrazine: a=b=c=34.2896(3) Å, α=β=γ=90°, V=40316.8(6) Å;'}{'sup': '3', 'manganese-1,2-bis((5H-imidazol-4-yl)methylene)hydrazine: a=b=c=35.7950(4) Å, α=β=γ=90°, V=45863.4(9) Å;'}{'sup': '3', "nickel-1,2-bis((5H-imidazol-4-yl)methylene)hydrazine: a=b=c=33.8514(19), α=β=γ=90°, V=38791(4) Å; wherein metal atoms of the nickel-1,2-bis((5H-imidazol-4-yl)methylene)hydrazine adopt a six-coordinate octahedral configuration; and metal atoms ...

Подробнее
03-04-2014 дата публикации

Catalyst Compositions Containing Transition Metal Complexes With Thiolate Ligands

Номер: US20140094577A1
Автор: Mark L. Hlavinka
Принадлежит: Chevron Phillips Chemical Co LP

The present invention discloses catalyst compositions employing transition metal complexes with a thiolate ligand. Methods for making these transition metal complexes and for using such compounds in catalyst compositions for the polymerization of olefins also are provided.

Подробнее
03-01-2019 дата публикации

MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING

Номер: US20190001003A1
Принадлежит:

Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets. 228.-. (canceled)30. (canceled)31. (canceled)3343.-. (canceled)52. The compound of claim 49 , wherein Ris 1 claim 49 ,2-cyclohexylene claim 49 , Ris H claim 49 , Ris H claim 49 , DG is Formula II claim 49 , Q is CH claim 49 , the Y positioned α- to Q is C-[L]-TBM claim 49 , and all other Y are CH claim 49 , and L is —C(O)—.54. A method of magnetic resonance (MR) imaging a patient claim 49 , the method comprising:{'claim-ref': {'@idref': 'CLM-00049', 'claim 49'}, 'a) administering to the patient an effective amount of a compound of ; and'}b) acquiring an MR image of the patient.55. The method of claim 54 , wherein the method is for imaging a tumor claim 54 , a blood clot claim 54 , or a brain lesion in a patient.56. (canceled)57. (canceled)58. A method for detecting the presence or absence of disrupted blood-brain-barrier in a patient claim 54 , the method comprising:{'claim-ref': {'@idref': 'CLM-00049', 'claim 49'}, 'a) administering to the patient an effective amount of a compound of ;'}b) acquiring a first MR image of the brain of the patient;c) acquiring a second MR image of the brain of the patient; andd) comparing the images.59. A method for detecting the presence or absence of arterial stenosis in a patient claim 54 , the method comprising:{'claim-ref': {'@idref': 'CLM-00049', 'claim 49'}, 'a) administering to the patient an effective amount of a compound of ;'}b) acquiring a first MR image of the arteries of a patient;c) acquiring a second MR image of the arteries of patient immediately after injection of the compound; andd) comparing the images. This application claims priority to U.S. Provisional Application Ser. No. 62/204,519, filed on Aug. 13, 2015, and U.S. Provisional ...

Подробнее
03-01-2019 дата публикации

SYNTHESIS OF HYPERVALENT IODINE REAGENTS WITH DIOXYGEN

Номер: US20190002487A1
Принадлежит: The Texas A&M University System

Methods of synthesis of hypervalent iodine reagents and methods for oxidation of organic compounds are disclosed. 1. A method of synthesis of an aryl hypervalent iodine reagent , comprising contacting an aryl iodide in a suitable solvent with an aliphatic aldehyde and a source of dioxygen , thereby forming the aryl hypervalent iodine reagent.2. The method of claim 1 , wherein the aryl hypervalent iodine reagent is aryl iodine I(III) or I(V) reagent.8. The method of claim 1 , wherein the aliphatic aldehyde has the formula of RCHO claim 1 , wherein Ris a C-Calkyl.9. The method of claim 8 , wherein the aliphatic aldehyde is acetaldehyde claim 8 , propionaldehyde claim 8 , or butyraldehyde.10. The method of claim 1 , wherein the suitable solvent is a coordinating solvent claim 1 , a non-coordinating solvent claim 1 , or a protic solvent.11. The method of claim 10 , wherein the suitable solvent is 1 claim 10 ,2-dichloroethane claim 10 , nitromethane claim 10 , acetic acid claim 10 , or acetonitrile.12. The method of claim 1 , wherein the contacting is performed in the presence of an autooxidation initiator.13. The method of claim 12 , wherein the autooxidation initiator is CoCl.6HO claim 12 , Cu(OAc).HO claim 12 , or Mn(OAc).4HO.14. The method of claim 1 , wherein the source of dioxygen is air or dioxygen gas.15. The method of claim 1 , wherein the method is performed at an atmospheric pressure.16. The method of claim 1 , wherein the method is performed at a temperature between about 20° C. and about 30° C.17. A method of oxidizing an organic compound claim 1 , the method comprising contacting an organic compound in a suitable solvent with an aryl iodide claim 1 , an aliphatic aldehyde claim 1 , and dioxygen claim 1 , thereby oxidizing the organic compound.18. The method of claim 17 , wherein the aryl iodide is an optionally substituted phenyl iodide.19. The method of claim 17 , wherein the suitable solvent is 1 claim 17 ,2-dichloroethane.20. The method of claim 17 , ...

Подробнее
01-01-2015 дата публикации

Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment

Номер: US20150005259A1
Принадлежит:

A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R, R, R, and Rare as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient. 2. A mixed metal complex according to claim 1 , wherein Ris hydroxy claim 1 , Calkoxy claim 1 , ethylene glycol claim 1 , glycerol claim 1 , amino or Calkylamido; Z is a bond or a group selected from CH claim 1 , (CH) claim 1 , CO claim 1 , CHCO claim 1 , CHCHCO and CHCOCH; Y is a bond; Ris a mono- or poly(hydroxy or alkoxylated) alkyl group or of the formula OP(O)(OR)R; and Ris hydroxy claim 1 , or an unsubstituted alkyl or aminoalkyl group.3. A mixed metal manganese complex according to claim 1 , wherein Ris ethylene and each group Rrepresents —CHCORin which Ris hydroxy.4. A mixed metal complex according to claim 1 , wherein the compound of Formula I is N claim 1 ,N′-bis-(pyridoxal-5-phosphate)-ethylenediamine-N claim 1 ,N′-diacetic acid (DPDP) or claim 1 , N claim 1 ,N′-dipyridoxyl ethylenediamine-N claim 1 ,N′-diacetic acid (PLED) claim 1 , or a pharmaceutically acceptable salt thereof.5. A mixed metal complex according to claim 1 , wherein the Group III-XII transition metal is Mn claim 1 , Cu claim 1 , Fe and/or Ni and the Group II metal is Ca and/or Mg.6. A mixed metal complex according to claim 1 , wherein the Group III-XII transition metal is Mn and the Group II metal is Ca or a mixture of Ca and Mg.7. A mixed metal complex according to claim 6 , wherein the Group II metal is a mixture of Ca and Mg in a Ca/Mg molar ratio of about 0.1-50.8. A mixed metal complex according to claim ...

Подробнее
11-01-2018 дата публикации

WATER SPLITTING CATALYST CONTAINING Mn4CaO4 CORE STRUCTURE, PREPARATION PROCESS AND APPLICATION THEREOF

Номер: US20180008969A1
Принадлежит:

The present invention provides a process for preparing a water splitting catalyst containing [MnCaO] core structure and use thereof. The present invention provides clusters containing [MnCaO] core structure by a chemical synthesis using inexpensive metal ions (Mn, Ca ions), simple carboxyl ligands and a permanganate, performed single crystal X-ray diffraction on their space structure, and characterized their physical and chemical properties with electron spectrum, electrochemical and electron paramagnetic resonance technologies and the like. These compounds can catalyze water splitting in the presence of oxidant to release oxygen and can also catalyze water splitting on the surface of an electrode to release electrons onto the surface of the electrode to form a current. 2. The compound according to claim 1 , characterized in that the valence states of the four Mn ions are +3 claim 1 , +3 claim 1 , +4 and +4 respectively claim 1 , and the whole cluster is electrically neutral.3. The compound according to claim 1 , characterized in that the carboxylic acid anion (RCO—) is selected from the group consisting of formic acid claim 1 , acetic acid claim 1 , propionic acid claim 1 , butyric acid claim 1 , isobutyric acid claim 1 , valeric acid claim 1 , isovaleric acid claim 1 , pivalic acid claim 1 , hexanoic acid and other carboxylic acid anions; that is claim 1 , Rcan be hydrogen (H) claim 1 , methyl (—CH) claim 1 , ethyl (—CH) claim 1 , n-propyl (—CHCHCH) claim 1 , isopropyl (—CH(CH)) claim 1 , n-butyl claim 1 , isobutyl claim 1 , tert-butyl (—C(CH)) claim 1 , n-pentyl (—(CH)CH) claim 1 , and isopentyl (—CH(CH)CH).4. The compound according to claim 1 , characterized in that the compound is selected from any of the following compounds:{'sub': 4', '4', '1', '2', '8', '1', '2', '3', '1', '1', '2', '3, '[MnCaO(RCO)](L)(L)(L), wherein R=tert-butyl; L=pyridine; L=L=pivalic acid;'}{'sub': 4', '4', '1', '2', '8', '1', '2', '3', '1', '1', '2', '3, '[MnCaO(RCO)](L)(L)(L), wherein ...

Подробнее
14-01-2016 дата публикации

METAL COMPLEXES OF POLY(CARBOXYL)AMINE-CONTAINING LIGANDS HAVING AN AFFINITY FOR CARBONIC ANHYDRASE IX

Номер: US20160009664A1
Принадлежит: Molecular Insight Pharmaceuticals

The present invention b directed to CA IX inhibitors that conform to Formula I where the substituents X, A, B, D, E, E′ and G are as defined above. 2. The ligand of claim 1 , wherein X is —(CH)— and m is 2.3. The ligand of claim 1 , wherein X is —O— and m is 4.4. The ligand of claim 1 , wherein Rand Rare each independently substituted or unsubstituted carboxy(C-C)alkylene claim 1 , Ris substituted or unsubstituted carboxy(C-C)alkylene.5. The ligand of claim 1 , wherein Rand Rare each independently claim 1 , —CHCOOH claim 1 , and Ris —C(CHCHCOOH).6. The ligand of claim 1 , wherein G and G′ are —(CH(R))—R— claim 1 , and Ris NRR claim 1 , or —COH.7. The ligand of claim 1 , wherein each of Rand Ris —C(CHCHCOOH.8. The ligand of claim 1 , wherein the compound is an inhibitor of carbonic anhydrase-IX.11. The metal complex of claim 10 , wherein M is Tc claim 10 , Re claim 10 , or Re.13. The metal complex of claim 12 , wherein M is Tc claim 12 , Re claim 12 , or Re.15. The ligand of in which the ICvalue is lower by a factor of at least 10.16. The ligand of in which the ICvalue is lower by a factor of at least 100.17. The ligand of in which the ICvalue is lower by a factor of at least 200.18. The ligand of in which the ICvalue is lower by a factor from 2 to about 200. This application is a continuation of application Ser. No. 13/734,534. filed Jan. 4, 2013 which claims the benefit of the priority date of U.S. Provisional Application No. 61/584,146, filed Jan. 6, 2012, the complete disclosure of which is incorporated herein by reference in its entirely.The present technology relates generally to the field of radiopharmaceuticals and their use in nuclear medicine for the treatment of various disease states. It is well known that tumors may express unique proteins associated with their malignant phenotype or may over-express normal constituent proteins as compared to the expression of these proteins in normal cells. The expression of distinct proteins on the surface of tumor ...

Подробнее
11-01-2018 дата публикации

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Номер: US20180009767A9
Принадлежит:

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 3. The composition of claim 2 , wherein the composition is adapted for administration to a subject.4. The composition of claim 3 , wherein the composition comprises a unit dosage form of compound (3).5. The composition of claim 4 , wherein the unit dosage form delivers to the subject an amount of compound (3) between about 0.01 and about 8 mg/kg.6. The composition of claim 5 , wherein the unit dosage form delivers to the subject an amount of compound (3) of about 0.01 mg/kg claim 5 , about 0.05 mg/kg claim 5 , about 0.10 mg/kg claim 5 , about 0.20 mg/kg claim 5 , about 0.3 mg/kg claim 5 , about 0.35 mg/kg claim 5 , about 0.40 mg/kg claim 5 , about 0.45 mg/kg claim 5 , about 0.50 mg/kg claim 5 , about 0.55 mg/kg claim 5 , about 0.60 mg/kg claim 5 , about 0.65 mg/kg claim 5 , about 0.70 mg/kg claim 5 , about 0.75 mg/kg claim 5 , about 0.80 mg/kg claim 5 , about 0.90 mg/kg claim 5 , about 1 mg/kg claim 5 , about 2 claim 5 , mg/kg claim 5 , about 4 mg/kg claim 5 , about 6 mg/kg claim 5 , or about 8 mg/kg.7. The composition of claim 2 , wherein the composition is in a single dose form.8. The composition of claim 2 , wherein the composition is in dry form.9. The composition of claim 2 , wherein the composition is lyophilized in a sterile container.10. The composition of claim 2 , wherein the composition is contained within a sterile container.11. The composition of claim 10 , wherein the sterile container comprises a machine detectable identifier.12. The composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients in an oral dosage form.13. The composition of claim 2 , further comprising one or more pharmaceutically acceptable carriers in an injectable dosage form.14. The composition of claim 2 , further ...

Подробнее
10-01-2019 дата публикации

Method of preparing luminescent nano-sheet, luminescent nano-sheet material, luminescent nano-sheet film, back light, and liquid crystal display apparatus

Номер: US20190010393A1
Автор: Haizheng Zhong, Lige Liu

The present application discloses a method of preparing a luminescent nano-sheet. The method includes preparing a precursor emulsion solution containing a metal halide and RNH3X, and having a molar ratio of metal halide to RNH3X in a range of approximately 0.6 to approximately 0.8; demulsifying the precursor emulsion solution to obtain a perovskite quantum dots material and a demulsified solution; and forming the luminescent nano-sheet by allowing the perovskite quantum dots material self-assemble into the luminescent nano-sheet. X is a halide, R is selected from alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and heterocyclyl.

Подробнее
21-01-2021 дата публикации

MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING

Номер: US20210015948A1
Принадлежит:

Provided herein are examples of metal chelating ligands that have high affinity for manganese. The resultant metal complexes can be used as MRI contrast agents, and can be functionalized with moieties that bind to or cause relaxivity change in the presence of biochemical targets. 3. The compound of claim 1 , wherein Q is CH.4. The compound of claim 1 , wherein Y is CH.5. The compound of claim 1 , wherein at least one Y is CZ claim 1 , wherein Z is selected from the group consisting of COR claim 1 , C-Calkyl claim 1 , and OR.6. The compound of claim 1 , wherein one Y is CZ claim 1 , wherein Z is selected from the group consisting of COR claim 1 , C-Calkyl claim 1 , and OR claim 1 , and all other Y are CH.7. The compound of claim 1 , wherein each Ris H or C-Calkyl claim 1 , wherein the alkyl is optionally substituted by 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 OH groups.8. The compound of claim 1 , wherein Rand Rare each H.919.-. (canceled)20. The compound of claim 1 , wherein Ris C-Ccycloalkylene.23. The compound of claim 1 , wherein Ris a C-Calkylene.24. (canceled)26. The compound of claim 1 , wherein Ris H.27. The compound of claim 1 , wherein Ris H.2948.-. (canceled)52. The compound of claim 49 , wherein for each Dand D claim 49 , Ris 1 claim 49 ,2-cyclohexylene claim 49 , Ris H claim 49 , Ris H claim 49 , DG is Formula II claim 49 , Q is CH claim 49 , the Y positioned α- to Q is C-(L)-TBM or C-(L)-TBM claim 49 , and all other Y are CH claim 49 , and Land Lare each —C(O)—.54. A method of magnetic resonance (MR) imaging a patient claim 49 , the method comprising:{'claim-ref': {'@idref': 'CLM-00049', 'claim 49'}, 'a) administering to the patient an effective amount of a compound of ; and'}b) acquiring an MR image of the patient.5559.-. (canceled)61. The compound of claim 49 , wherein Q is CH.62. The compound of claim 49 , wherein Y is CH.63. The compound of claim 49 , wherein at least one Y is CZ claim 49 , wherein Z is selected from the group consisting of COR ...

Подробнее
17-04-2014 дата публикации

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20140102365A1
Принадлежит:

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands. 1. A metal coordinating ligand having a formula{'sub': 1', '2', 'x', 'y', '7', '8', '1-6', '2-4', '1', '2', '7', '8', '3', '4', '5', '6, 'a) RRN—(CR)—N—(CR)—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl and x and y are independently 2-6, provided that when each of R, R, Rand Ris ethyl, at least one of R, R, Rand Ris not H;'}{'sub': 1', '2', '1', '2', '3', '4', '1-6', '2-4', '1', '2', '1', '2', '3', '4, 'b) RRN—Ar—NH—Ar—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Arand Arare aromatic hydrocarbon moieties which may be the same or different, provided that at least one of R, R, Rand Ris not methyl;'}{'sub': 1', '2', '3', '4', 'x', 'Ar', '5', '6', 'y', '7', '8', '1-6', '2-4', 'Ar', '1', '2', '3', '4, 'c) RRN—(CRR)—N—(CRR)—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Nis a heterocyclic aromatic moiety wherein the heteroatom is N, provided that at least one of R, R, Rand Ris not methyl, or;'}{'sub': Ar1', '1', '2', 'x', '5', '3', '4', 'y', 'Ar2', '1-6', '2-4', 'Ar1', 'Ar2, 'd) N—(CRR)—NR—(CRR)—N, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Nand Nmay be the same or different and are heterocyclic aromatic moieties wherein the heteroatom is N.'}3. The metal coordinating ligand of claim 2 , wherein R claim 2 , R claim 2 , Rand Rof formula I are each ethyl (Et) and each of R-Ris independently hydrogen claim 2 , Calkyl claim 2 , acyl claim 2 , aldehyde claim 2 , keto or Calkenyl.4. An apparatus comprising:a deposition chamber; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the metal coordinating ligand of ...

Подробнее
22-01-2015 дата публикации

RADIOTRACER PRECURSOR BANI FOR IMAGING OF HYPOXIC TISSUE, RADIOTRACER, AND METHOD FOR PREPARING THE SAME

Номер: US20150025248A1

The present invention relates to a radiotracer precursor for imaging of hypoxic tissues, a radiotracer and a method for preparing the same. The radiotracer precursor, BANI, includes a nitroimidazole functional group with a feature of retention in hypoxic tissues and a bifunctional ligand able to complex with radioisotopes. Thus BANI can be used to produce radiotracers retained in hypoxic tissues and the radiotracers are applied to medical imaging of malignant tumor with hypoxic layer. 2. The precursor as claimed in claim 1 , wherein compounds having the structural formula are used to prepare radiotracers for imaging of hypoxic tissues.3. A method for preparing a radiotracer precursor comprising the steps of:hydrolyzing methyl-DL-2,3-bis[((triphenylmethyl)-thio)acetamido]propionate to get DL-2,3-Bis-[((triphenylmethyl)thio)acetamido]propionic acid;using 6-aminohexanol and DL-2,3-Bis-[((triphenyl-methyl)thio)acetamido]propionic acid to carry out amidation and get 6-hydroxyhexyl DL-2,3-Bis[((triphenylmethyl)thio)acetamido]propanamide;using P-toluenesulfornyl chloride and 6-hydroxyhexyl DL-2,3-Bis[((triphenylmethyl)thio)acetamido]-propanamide to perform a substitution reaction and produce 6-toluenesulfonylhexyl-DL-2,3-Bis-[((triphenylmethyl)-thio)acetamido]propanamide; andtaking 2-nitroimidazole and 6-toluenesulfonylhexyl-D L-2,3-Bis[((triphenyl-methyl)-thio)acetamido]propanamide to carry out substitution reaction and get 6-(2-nitroimidazole)hexyl-DL-2,3-Bis-[((triphenylmethyl)thio)acetamido]propanamide.4. The method as claimed in claim 3 , wherein a method for preparing DL-2 claim 3 ,3-bis[((triphenylmethyl)-thio)-acetamido]propionate includes the steps of:using a triphenylmethyl group to protect a thiol group of thioglycolic acid methyl ester and get triphenylmethyl thioglycolic acid methyl ester;hydrolyzing triphenylmethyl thioglycolic acid methyl ester to produce triphenylmethyl thioglycolic acid;performing esterification of DL-2,3-diaminopropionic acid in methanol ...

Подробнее
28-01-2021 дата публикации

TRICARBONYL COMPLEXES OF TRANSITION METALS WITH BENZO-HETEROCYCLIC DERIVATIVES OF THE CYCLOPENTADIENYL ANION

Номер: US20210024555A1

Complex compounds of transition metals according to formula (1) wherein the M(CO) tricarbonyl-metal core forms a complex with the cyclopentadienyl anion linked to heterocyclic moieties of the benzothiazole, benzimidazole and benzoxazole families. The compounds exhibit high blood-brain barrier permeability and can be used in the diagnosis and/or treatment of diseases of the Central Nervous System. 118.-. (canceled)20. A compound according to or a pharmaceutically acceptable salt thereof claim 19 , wherein R claim 19 , Rare the same.21. A compound according to or a pharmaceutically acceptable salt thereof claim 19 , wherein the alkyl- claim 19 , haloalkyl- claim 19 , aminoalkyl- claim 19 , alkylamino- claim 19 , alkyloxy- claim 19 , has 1 to 6 carbon atoms.22. A compound according to or a pharmaceutically acceptable salt thereof claim 19 , wherein Rand/or Ris hydrogen.23. A compound according to or a pharmaceutically acceptable salt thereof claim 19 , wherein M is Tc claim 19 , A is C—H claim 19 , B is C—H claim 19 , C is C—H claim 19 , D is C—H claim 19 , Ris H claim 19 , Ris H claim 19 , X is S claim 19 , O claim 19 , N and when X is N claim 19 , Ris H or CH.24. A compound according to or a pharmaceutically acceptable salt thereof claim 23 , wherein Tc is Tc.26. A compound or a pharmaceutically acceptable salt thereof for use according to claim 25 , wherein M is Re or Tc.27. A compound or a pharmaceutically acceptable salt thereof for use according to claim 26 , wherein M is Tc.28. A compound or a pharmaceutically acceptable salt thereof for use according to claim 25 , wherein M is Re or Tc claim 25 , A is C—H claim 25 , B is C—H claim 25 , C is C—H claim 25 , D is C—H claim 25 , Ris H claim 25 , Ris H claim 25 , X is S claim 25 , O claim 25 , N and when X is N claim 25 , Ris H or CH.29. A compound or a pharmaceutically acceptable salt thereof for use according to claim 31 , wherein Tc is Tc.30. A compound or a pharmaceutically acceptable salt thereof for use ...

Подробнее
17-02-2022 дата публикации

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Номер: US20220048872A1
Принадлежит:

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 5. A compound according to claim 1 , wherein Ris COH and Ris H or Ris COH and Ris H.6. A compound according to claim 1 , wherein Ris CORand Ris H or Ris COR claim 1 , and Ris H.7. A compound according to claim 1 , wherein Ris H claim 1 , and Ris H.8. A compound according to claim 1 , wherein Ris C-Caryl claim 1 , or alkylaryl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms.9. A compound according to claim 1 , wherein Ris C-Caryl.10. A compound according to wherein Ris phenyl.11. A compound according to claim 1 , wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.12. A compound according to claim 1 , wherein FG comprises carbocyanine claim 1 , indocarbocyanine claim 1 , oxacarbocyanine claim 1 , thiacarbocyanine and merocyanine claim 1 , polymethine claim 1 , coumarine claim 1 , rhodamine claim 1 , xanthene claim 1 , fluorescein claim 1 , boron-dipyrromethane (BODIPY) claim 1 , Cy5 claim 1 , Cy5.5 claim 1 , Cy7 claim 1 , VivoTag-680 claim 1 , VivoTag-S680 claim 1 , VivoTag-S750 claim 1 , AlexaFluor660 claim 1 , AlexaFluor680 claim 1 , AlexaFluor700 claim 1 , AlexaFluor750 claim 1 , AlexaFluor790 claim 1 , Dy677 claim 1 , Dy676 claim 1 , Dy682 claim 1 , Dy752 claim 1 , Dy780 claim 1 , DyLight547 claim 1 , Dylight647 claim 1 , HiLyte Fluor 647 claim 1 , HiLyte Fluor 680 claim 1 , HiLyte Fluor 750 claim 1 , IRDye 800CW claim 1 , IRDye 800RS claim 1 , IRDye 700DX claim 1 , ADS780WS claim 1 , ADS830WS claim 1 , and ADS832WS.15. A method of imaging one or more cells claim 1 , organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a fluorescent dye moiety suitable for imaging.16 ...

Подробнее
16-02-2017 дата публикации

PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY

Номер: US20170042907A1
Принадлежит:

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X. 138-. (canceled)40. A pharmaceutical composition comprising the pentaaza macrocyclic ring complex of and a pharmaceutically acceptable excipient.41. The pharmaceutical composition of wherein the composition comprises linoleoyl polyoxyl-6 glycerides (NF).42. The pharmaceutical composition of wherein the pharmaceutical composition is suitable for oral administration to a human subject.43. The pharmaceutical composition of wherein the pharmaceutical composition is in a solid or semi-solid dosage form.44. The pharmaceutical composition of wherein the pharmaceutical composition is in the form of a tablets claim 40 , gelatin capsules claim 40 , HPMC capsules claim 40 , gel or suspension suitable for oral administration.45. The pharmaceutical composition of wherein the pharmaceutical composition comprises an enteric coating layer. The present disclosure generally relates to transition metal pentaaza 15-membered macrocyclic ring complexes which have improved properties, including significant oral bioavailability.Transition metal pentaaza 15-membered macrocyclic ring complexes having the macrocyclic ring system corresponding to Formula A have been shown to be effective in a number of animal and cell models of human disease, as well as in treatment of conditions afflicting human patients.For example, in a rodent model of colitis, one such compound, GC4403, has been reported when administered by intraperitoneal (ip) injection to significantly reduce the injury to the colon of rats subjected to an experimental model of colitis (see Cuzzocrea et al., 432, 79-89 (2001)).GC4403 administered ip has also been reported to attenuate the radiation damage arising both in a clinically ...

Подробнее
16-02-2017 дата публикации

Heterodimers of Glutamic Acid

Номер: US20170044098A1
Принадлежит: Molecular Insight Pharmaceuticals Inc

Compounds of Formula (Ia) wherein R is a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl, a C 1 -C 6 substituted or unsubstituted alkyl or —NR′R′, Q is C(O), O, NR′, S, S(O) 2 , C(O) 2 (CH 2 )p Y is C(O), O, NR′S, S(O) 2 , C(O) 2 (CH 2 )p Z is H or C 1- C 4 alkyl, R′ is H, C(O), S(O) 2 , C(O) 2 , a C 6 -C 12 substituted or unsubstituted aryl, a C 6 -C 12 substituted or unsubstituted heteroaryl or a C 1 -C 6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C 6 -C 12 heteroaryl, —NR′R′ or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition, Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.

Подробнее
16-02-2017 дата публикации

PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY

Номер: US20170044193A1
Принадлежит:

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X. 138-. (canceled)40. A pharmaceutical composition comprising the pentaaza macrocyclic ring complex of and a pharmaceutically acceptable excipient.41. The pharmaceutical composition of wherein the composition comprises at least one of mono/diglycerides and triglycerides of caprylic/capric acids.42. The pharmaceutical composition of claim 41 , wherein the composition comprises a mixture of caprylic/capric acid triglycerides.43. The pharmaceutical composition of wherein the pharmaceutical composition is suitable for oral administration to a human subject.44. The pharmaceutical composition of wherein the pharmaceutical composition is in a solid or semi-solid dosage form.45. The pharmaceutical composition of wherein the pharmaceutical composition is in the form of a tablets claim 40 , gelatin capsules claim 40 , HPMC capsules claim 40 , gel or suspension suitable for oral administration.46. The pharmaceutical composition of wherein the pharmaceutical composition comprises an enteric coating layer.48. A pharmaceutical composition comprising the pentaaza macrocyclic ring complex of and a pharmaceutically acceptable excipient.49. The pharmaceutical composition of wherein the composition comprises at least one of mono/diglycerides and triglycerides of caprylic/capric acids.50. The pharmaceutical composition of claim 48 , wherein the composition comprises a mixture of caprylic/capric acid triglycerides.51. The pharmaceutical composition of wherein the pharmaceutical composition is suitable for oral administration to a human subject.52. The pharmaceutical composition of wherein the pharmaceutical composition is in a solid or semi-solid dosage form.53. The pharmaceutical ...

Подробнее
16-02-2017 дата публикации

MOLECULARLY TUNABLE HETEROGENEOUS CATALYSTS BY EDGE FUNCTIONALIZATION OF GRAPHITIC CARBONS

Номер: US20170047592A1
Принадлежит:

Disclosed are surface immobilized (electro)catalysts that may be prepared by a condensation reaction that generates an aromatic unit that is robust to acid and base and elevated temperatures. Among their many desirable characteristics, the catalysts are far less prone to the bimolecular deactivation pathways commonly observed for homogeneous catalysts, and may be used in solvents with a range of polarities and dielectric strengths. The catalysts are suitable for a wide array of thermal catalytic reactions (polymerization, oxidation, hydrogenation, cross-coupling etc.) and as anodes and/or cathodes in fuel cells, electrolyzers, and in batteries and supercapacitors. 2. The composition of claim 1 , wherein A is a mono- claim 1 , bi- claim 1 , tri- claim 1 , or polycyclic aryl moiety.3. The composition of claim 2 , wherein A is benzo.4. The composition of claim 1 , wherein n is 1.8. The composition of claim 1 , wherein M is present; and X claim 1 , R claim 1 , and L are absent; and M is associated with additional ligands.10. The composition of claim 1 , wherein the graphene is present in a form selected from the group consisting of reduced graphene oxide claim 1 , graphene nanoribbon claim 1 , graphene quantum dots claim 1 , glassy carbon claim 1 , pyrolytic graphite claim 1 , graphite powder claim 1 , Vulcan carbon claim 1 , monarch carbon claim 1 , ketjen black claim 1 , single-walled carbon nanotubes claim 1 , and multi-walled carbon nanotubes.11. An electrochemical half-cell claim 1 , comprising the composition of .12. A fuel cell claim 1 , comprising a first electrochemical half-cell comprising the composition of ; a second electrochemical half-cell; and an electrolyte in contact with the first electrochemical half-cell and the second electrochemical half-cell.13. A catalytic reactor claim 1 , comprising the composition of .15. The method of claim 14 , wherein A is a mono- claim 14 , bi- claim 14 , tri- claim 14 , or polycyclic aryl moiety.16. The method of claim ...

Подробнее
23-02-2017 дата публикации

ANTIOXIDANT COMPOUNDS AND THEIR USE

Номер: US20170050996A1

Disclosed herein are novel amine-functionalized porphyrin compounds, as wells as pharmaceutically acceptable salts or esters thereof. The disclosed compounds can be used to impart antioxidant, anti-inflammatory, anti-microbial, and/or cell-adhesion specificity to a surface or material in need thereof, such as a surface of an indwelling medical implant, or a marine surface. 2. The compound claim 1 , salt claim 1 , or ester of claim 1 , wherein A is independently an optionally substituted azetyl claim 1 , an optionally substituted pyrrolyl claim 1 , an optionally substituted pyridinyl claim 1 , an optionally substituted azepinyl claim 1 , or an optionally substituted azocinyl.3. The compound claim 2 , salt claim 2 , or ester of claim 2 , wherein A is an optionally substituted pyridinyl.6. The compound claim 1 , salt claim 1 , or ester of claim 1 , wherein x is 0 or 1.7. The compound claim 1 , salt claim 1 , or ester of claim 1 , wherein Ris aminoethyl.8. The compound claim 1 , salt claim 1 , or ester of claim 1 , wherein M is magnesium claim 1 , iron claim 1 , or not present.9. The compound claim 1 , salt claim 1 , or ester of claim 1 , comprising a structure set forth as any one of Structure 5-39.11. The medical implant of claim 10 , comprising:(A), and wherein the implant is one of: a dental implant, a heart valve, a vascular stent, a neural tissue implant, an orthopedic implant, a pacemaker, an electoral lead, a neural probe for recording and/or stimulating a neural signal in a subject; or a medical catheter; or(B), and wherein the implant is one of: a dental implant, a heart valve, a vascular stent, an orthopedic implant; or a medical catheter.12. The medical implant of claim 10 , wherein the surface comprises from about 1 ng/mmto about 10 ng/mmof the compound.13. The medical implant of claim 10 , wherein A is independently an optionally substituted azetyl claim 10 , an optionally substituted pyrrolyl claim 10 , an optionally substituted pyridinyl claim 10 , an ...

Подробнее
27-02-2020 дата публикации

MANGANESE CHELATE COMPOUNDS

Номер: US20200062791A1
Принадлежит:

The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds. 2. The compound as defined in wherein X is O claim 1 , Y is Q-Rwherein Q is N and Z is Q-R-(L-R) wherein Q is N.3. The compound as defined in wherein X is S claim 1 , Y is Q-Rwherein Q is N and Z is Q-R-(L-Rwherein Q is N.4. The compound as defined in wherein X is O claim 1 , either Y is O or Z is O-L-Rand when Y is not O it is Q-Rwherein Q is N and when Z is not O-L-Rit is Q-R-(L-R) wherein Q is N.5. The compound as defined in wherein X is S claim 1 , either Y is O or Z is O-L-Rand when Y is not O it is Q-Rwherein Q is N and when Z is not O it is Q-R-(L-R) wherein Q is N.6. The compound as defined in wherein X is O claim 1 , Y is Q-Rwherein Q is N and Z is Q-R-(L-R) wherein Q is CH.7. The compound as defined in wherein X is O claim 1 , either Y is O or Z is O-L-Rand when Y is not O it is Q-Rwherein Q is CH and when Z is not O it is Q-R-(L-R) wherein Q is CH.8. The compound as defined in wherein each -L-Ris Chydroxyalkyl.910-. (canceled)1217-. (canceled)18. The compound as defined in wherein each Ris the same.19. The compound as defined in wherein each Ris independently selected Calkyl or hydrogen.20. The compound as defined in wherein each Ris Calkyl.21. (canceled)22. The compound as defined in wherein each Ris hydrogen.23. The compound as defined in wherein each Ris the same.24. The compound as defined in wherein each n is an integer from 1-6.25. (canceled)26. The compound as defined in wherein m is 3.27. The compound as defined in wherein Ris Calkyl.28. (canceled)29. The compound as defined in wherein Ris —(CH)—Y—C(═X)—Z wherein X claim 1 , Y claim 1 , Z and m are as defined in any one of -.30. The compound as defined in wherein Rrepresents 0 substituents.31. The compound as defined in wherein Rrepresents 2 hydroxy ...

Подробнее
16-03-2017 дата публикации

Carbon monoxide releasing rhenium compounds for medical use

Номер: US20170071981A1
Принадлежит: Universitaet Zuerich

The present invention relates to new rhenium compounds of formula (I) with medical utility, corresponding pharmaceutical compositions as well as medical uses thereof.

Подробнее
14-03-2019 дата публикации

METAL-ORGANIC HYBRID STRUCTURES BUILT WITH MULTI-DIRECTIONAL POLYDENTATE LIGANDS

Номер: US20190077788A1
Принадлежит:

A compound represented by Chemical Formula 1 according to the present invention can coordinate with metal ions to form a bidirectional or multidirectional metal-organic hybrid structure. Thus, the present invention can synthesize various ligands using amine-aldehyde condensation, and synthesize metal-organic materials using the same. 2. The metal-organic hybrid structure according to claim 1 , wherein wherein R's are each independently —OH claim 1 , phenyl claim 1 , naphthyl claim 1 , methyl claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , butyl claim 1 , isobutyl claim 1 , tert-butyl claim 1 , pentyl claim 1 , tert-pentyl claim 1 , neopentyl claim 1 , isopentyl claim 1 , sec-pentyl claim 1 , 3-pentyl claim 1 , or an amino acid residue selected from the group consisting of alanine claim 1 , cysteine claim 1 , aspartic acid claim 1 , glutamic acid claim 1 , phenylalanine claim 1 , histidine claim 1 , isoleucine claim 1 , lysine claim 1 , leucine claim 1 , methionine claim 1 , asparagine claim 1 , pyrrolysine claim 1 , glutamine claim 1 , arginine claim 1 , serine claim 1 , threonine claim 1 , selenocysteine claim 1 , valine claim 1 , tryptophan claim 1 , and tyrosine.3. The metal-organic hybrid structure according to claim 1 , wherein Ris methyl claim 1 , ethyl claim 1 , propyl claim 1 , isopropyl claim 1 , butyl claim 1 , isobutyl claim 1 , tert-butyl claim 1 , pentyl claim 1 , tert-pentyl claim 1 , neopentyl claim 1 , isopentyl claim 1 , sec-pentyl claim 1 , 3-pentyl claim 1 , hexyl claim 1 , octyl claim 1 , phenyl claim 1 , naphthyl claim 1 , or pyridinyl.5. The metal-organic hybrid structure according to claim 1 , wherein the metal of the metal ion is Period 1 transition metal claim 1 , Period 2 transition metal claim 1 , Period 3 transition metal claim 1 , or lanthanide metal.6. The metal-organic hybrid structure according to claim 1 , wherein the metal of the metal ion is Ti claim 1 , V claim 1 , Mn claim 1 , Fe claim 1 , Co claim 1 , Ni claim 1 , ...

Подробнее
05-03-2020 дата публикации

CYCLIC COMPOUND, ANODE FOR LITHIUM ION SECONDARY BATTERY, AND LITHIUM ION SECONDARY BATTERY

Номер: US20200075998A1
Принадлежит:

A lithium ion secondary battery includes a cathode, an anode, and an electrolytic solution. The anode includes a cyclic compound. The cyclic compound includes one or more of a first cyclic compound, a second cyclic compound, a third cyclic compound, a fourth cyclic compound, a fifth cyclic compound, and a sixth cyclic compound. 2. The lithium ion secondary battery according to claim 1 , wherein each of the M1 to the M26 includes one of tin (Sn) claim 1 , titanium (Ti) claim 1 , silicon (Si) claim 1 , copper (Cu) claim 1 , manganese (Mn) claim 1 , iron (Fe) claim 1 , niobium (Nb) claim 1 , nickel (Ni) claim 1 , cobalt (Co) claim 1 , aluminum (Al) claim 1 , and zirconium (Zr).3. The lithium ion secondary battery according to claim 1 , wherein each of the Y1 to the Y26 includes one of fluorine (F) claim 1 , chlorine (Cl) claim 1 , bromine (Br) claim 1 , and iodine (I).4. The lithium ion secondary battery according to claim 1 , wherein all of the X1 to the X8 include oxo groups or imino groups claim 1 , and all of the X9 to the X16 include oxo groups or imino groups.6. The lithium ion secondary battery according to claim 1 , whereinthe anode further includes a carbon material, a metal-based material, or both, anda weight ratio of the cyclic compound to the cyclic compound, the carbon material, and the metal-based material is 0.01 or more and 0.99 or less. The present application is a continuation of PCT patent application no. PCT/JP2018/017264, filed on Apr. 27, 2018, which claims priority to U.S. provisional patent application No. 62/492,657 filed on May 1, 2017, the entire contents of which are being incorporated herein by reference.The present technology generally relates to a cyclic compound having a cyclic structure, an anode, for a lithium ion secondary battery, that uses the cyclic compound, and a lithium ion secondary battery provided with the anode for a lithium ion secondary battery.As a result of widespread use of various electronic apparatuses, development ...

Подробнее
12-06-2014 дата публикации

Synthesis and Characterization of First Row Transition Metal Complexes Containing alpha-keto Hydrazonate Ligands as Potential Precursors for Use in Metal Film Deposition

Номер: US20140161977A1
Принадлежит: WAYNE STATE UNIVERSITY

A compound that is useful for forming a metal by reaction with a reducing agent is described by formula (I): 2. The compound of wherein M is Cr claim 1 , Mn claim 1 , Fe claim 1 , Co claim 1 , or Ni.3. The compound of wherein R claim 2 , R claim 2 , and Rare each independently methyl claim 2 , ethyl claim 2 , n-propyl claim 2 , isopropyl claim 2 , n-butyl claim 2 , sec-butyl claim 2 , isobutyl claim 2 , or t-butyl.4. The compound of selected from the group consisting of bis((1-tert-butyldiazenyl)-3 claim 1 ,3-dimethylbut-1-en-2-olate)chromium(II) claim 1 , bis((1-tert-butyldiazenyl)-3 claim 1 ,3-dimethylbut-1-en-2-olate)manganese(II) claim 1 , bis((1-tert-butyldiazenyl)-3 claim 1 ,3-dimethylbut-1-en-2-olate)iron(II) claim 1 , bis((1-tert-butyldiazenyl)-3 claim 1 ,3-dimethylbut-1-en-2-olate)cobalt(II) claim 1 , bis((1-tert-butyldiazenyl)-3 claim 1 ,3-dimethylbut-1-en-2-olate)nickel(II) claim 1 , bis((3-tert-butyldiazenyl)but-2-en-2-olate)iron(II) claim 1 , bis((3-tert-butyldiazenyl)but-2-en-2-olate)cobalt(II) claim 1 , bis((3-tert-butyldiazenyl)but-2-en-2-olate)nickel(II) claim 1 , and bis((1-tert-butyldiazenyl)-3-methylbut-1-en-2-olate)iron(II) claim 1 , bis((1-tert-butyldiazenyl)-3-methylbut-1-en-2-olate)cobalt(II) claim 1 , and bis((1-tert-butyldiazenyl)-3-methylbut-1-en-2-olate)nickel(II).6. The method of wherein the activating agent is a reducing agent.7. The method of wherein the reducing agent is selected from the group consisting of NHNMe claim 6 , NHNH claim 6 , AlEt claim 6 , AlMe claim 6 , HSiEt claim 6 , LiBHEt claim 6 , LiAlH claim 6 , BH.N(CH) claim 6 , BH.NH(CH) claim 6 , pinacol borane claim 6 , BH.S(CH) claim 6 , BH.THF claim 6 , BH.2-picoline claim 6 , decaborane claim 6 , 9-Borabicyclo[3.3.1]nonane (9-BBN) claim 6 , BH.morpholine claim 6 , and combinations thereof.8. The method of wherein the activating agent is an oxidizing agent or a nitriding agent.9. The method of wherein M is Cr claim 5 , Mn claim 5 , Fe claim 5 , Co claim 5 , or Ni.10. The ...

Подробнее
12-03-2020 дата публикации

METHODS OF MAKING NANOSTRUCTURED METAL-ORGANIC FRAMEWORKS

Номер: US20200079796A1
Принадлежит:

Disclosed herein are methods of making nanostructured metal-organic frameworks. The methods include contacting a homogenized ligand solution with a homogenized aqueous metal salt solution at room temperature to form a mixture; and agitating the mixture for an amount of time to thereby form the nanostructured metal-organic framework at room temperature; wherein the homogenized ligand solution comprises a ligand dispersed substantially homogenously in a solvent selected from the group consisting of water, ethanol, isopropanol, n-propanol, lactic acid, and combinations thereof; and wherein the homogenized aqueous metal salt solution comprises a metal salt dispersed substantially homogenously in an aqueous solvent. Also disclosed herein are nanostructured metal-organic frameworks made by the methods described herein. Also disclosed herein are articles of manufacture comprising nanostructured metal-organic frameworks made by the methods described herein, such as filters, respirators, gas masks, human protection devices, catalysts, and catalyst supports. 1. A method of making a nanostructured metal-organic framework , the method comprising:contacting a homogenized ligand solution with a homogenized aqueous metal salt solution at room temperature to form a mixture; andagitating the mixture for an amount of time to thereby form the nanostructured metal-organic framework at room temperature;wherein the homogenized ligand solution comprises a ligand dispersed substantially homogenously in a solvent selected from the group consisting of water, ethanol, isopropanol, n-propanol, lactic acid, and combinations thereof; andwherein the homogenized aqueous metal salt solution comprises a metal salt dispersed substantially homogenously in an aqueous solvent.2. The method of claim 1 , wherein the homogenized ligand solution comprises the ligand in an amount of from 0.05 to 0.1 gram per 100 mL of solvent.3. The method of claim 1 , wherein the ligand comprises 1 claim 1 ,3 claim 1 ,5- ...

Подробнее
19-03-2020 дата публикации

CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES

Номер: US20200087331A1
Принадлежит:

A chemoselective and reactive Mn(CF-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites. 2. The complex of wherein the complex is an (S claim 1 ,S) enantiomer.3. The complex of wherein the complex is an (R claim 1 ,R) enantiomer.4. The complex of wherein the complex is a salt and the anion of the salt is Cl claim 1 , Br claim 1 , AcO claim 1 , TfO claim 1 , CFCO claim 1 , BF claim 1 , ClO claim 1 , ReO claim 1 , AsF claim 1 , PF claim 1 , or SbF.5. The complex of wherein Land Lare each independently chloro claim 1 , acetone claim 1 , acetonitrile claim 1 , or a terminal oxo bridge; or Land Ltogether are a carboxylate group.6. The complex of wherein each Gand each Gis independently (C-C)alkyl substituted with one or more halo groups.7. The complex of wherein each Gis independently chloro claim 1 , methyl claim 1 , ethyl claim 1 , isopropyl claim 1 , teat-butyl claim 1 , —OCH claim 1 , —C(═O)OCH claim 1 , —C(═O)OC(CH) claim 1 , —CF claim 1 , —CFCH claim 1 , or —CFCF.8. The complex of wherein each Gis independently chloro claim 7 , methyl claim 7 , ethyl claim 7 , isopropyl claim 7 , teat-butyl claim 7 , —OCH claim 7 , —C(═O)OCH claim 7 , —C(═O)OC(CH) claim 7 , —CF claim 7 , —CFCH claim 7 , or —CFCF.9. The complex of wherein x and y are each independently 2 or 3; or{'sup': 3', '4, 'wherein Gand Gare at the 4-position of the pyridyl moiety of Formula I.'}11. The complex of wherein each Gand each Gis independently chloro claim 10 , methyl claim 10 , ethyl claim 10 , isopropyl claim 10 , teat-butyl claim 10 , —OCH claim 10 , —C(═O)OCH claim 10 , —C(═O)OC(CH) claim 10 , —CF claim 10 , —CFCH claim 10 , or —CFCF.12. The complex of wherein z is 0.13. The complex of wherein Rand Rare each —CH—.15. The ...

Подробнее
28-03-2019 дата публикации

METHODS OF USING MULTI-LIGAND METAL COMPLEXES TO PERFORM OXIDATIVE CATALYTIC PRETREATMENT OF LIGNOCELLULOSIC BIOMASS

Номер: US20190091674A1
Принадлежит:

A homogeneous catalyst is provided comprising one or more metals; and at least two metal coordinating ligands wherein the homogeneous catalyst is a multi-ligand metal complex_adapted for use with an oxidant in an oxidation reaction to catalytically pretreat lignocellulosic biomass. In one embodiment, the homogenous catalyst is copper (II) 2, 2′ bipyridine ethylenediamine (Cu(bpy)en). Related methods are also disclosed. 110-. (canceled)11. A method comprising:catalytically delignifying alkaline-pretreated lignocellulosic biomass with a homogeneous multi-ligand metal complex catalyst and an oxidant in an oxidation reaction, wherein said metal complex comprises a combination of a metal-ligand complex and at least one metal coordinating ligand selected from pyridine, 1,10-phenanthroline, ethylenediamene, histidine, glycine and combinations thereof, wherein radicals formed during the oxidation reaction react with lignin present in the alkaline-pretreated lignocellulosic biomass to solubilize the lignin to produce a catalytically delignified lignocellulosic biomass.12. The method of wherein the alkaline-pretreated lignocellulosic biomass claim 11 , the multi-ligand metal complex and the oxidant form a solution having a pH of at least 11.5.13. The method of wherein the oxidant is hydrogen peroxide claim 12 , the radicals formed during the oxidation reaction are hydroxyl radicals claim 12 , and the multi-ligand metal complex is a multi-ligand copper complex.14. The method of wherein the copper complex is a copper(II) 2 claim 13 ,2′-bipyridine complex (Cu(bpy)) modified to contain at least one additional metal-coordinating ligand.15. The method of wherein said additional metal-coordinating ligand is ethylenediamine.16. The method of wherein the oxidant is added at a gradual rate equal to or less than a rate of consumption of the oxidant by the alkaline-pretreated lignocellulosic biomass and the multi-ligand metal complex.17. (canceled)18. The method of wherein the method ...

Подробнее
16-04-2015 дата публикации

PSMA-TARGETING COMPOUNDS AND USES THEREOF

Номер: US20150104387A1
Принадлежит: THE JOHNS HOPKINS UNIVERSITY

Prostate-specific membrane antigen (PSMA) targeting compounds are described. Uses of the compounds for imaging, therapy, cell sorting, and tumor mapping are also described. 423-. (canceled)25. (canceled)26. A compound according to claim 1 , having a chelated metal claim 1 , wherein the chelated metal is Tc claim 1 , In claim 1 , Ga claim 1 , Y claim 1 , Lu claim 1 , Re claim 1 , Cu claim 1 , Ac claim 1 , Bi claim 1 , Pb claim 1 , Sm claim 1 , Sc claim 1 , Co claim 1 , Ho claim 1 , Gd claim 1 , Eu claim 1 , Tb claim 1 , or Dy.27. (canceled)28. (canceled)30. (canceled)31. (canceled)3244-. (canceled)45. (canceled)46. (canceled)47. (canceled)48. (canceled)49. (canceled)5274-. (canceled)75. A compound according to wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.76. A compound according to wherein FG comprises carbocyanine claim 1 , indocarbocyanine claim 1 , oxacarbocyanine claim 1 , thiacarbocyanine and merocyanine claim 1 , polymethine claim 1 , coumarine claim 1 , rhodamine claim 1 , xanthene claim 1 , fluorescein claim 1 , boron-dipyrromethane (BODIPY) claim 1 , Cy5 claim 1 , Cy5.5 claim 1 , Cy7 claim 1 , VivoTag-680 claim 1 , VivoTag-S680 claim 1 , VivoTag-S750 claim 1 , AlexaFluor660 claim 1 , AlexaFluor680 claim 1 , AlexaFluor700 claim 1 , AlexaFluor750AlexaFluor790 claim 1 , Dy677 claim 1 , Dy676 claim 1 , Dy682 claim 1 , Dy752 claim 1 , Dy780 claim 1 , DyLight547 claim 1 , Dylight647 claim 1 , HiLyte Fluor 647 claim 1 , HiLyte Fluor 680 claim 1 , HiLyte Fluor 750 claim 1 , IRDye 800CW claim 1 , IRDye 800RS claim 1 , IRDye 700DX claim 1 , ADS780WS claim 1 , ADS830WS claim 1 , and ADS832WS.81102-. (canceled)104112-. (canceled)116145-. (canceled)146. A method of imaging one or more cells claim 1 , organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a fluorescent dye moiety claim 1 , or a metal isotope suitable for imaging.147. ...

Подробнее
26-03-2020 дата публикации

WATER SOLUBLE ANIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND THEIR USES

Номер: US20200094069A1
Принадлежит:

The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<->, COS<->, SO3<->, PO3<2->, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis. 150-. (canceled)51. A method of treating a tumor in a patient by vascular-targeted photodynamic therapy (VTP) , the method comprising:(a) administering to a patient having a tumor an effective amount of a compound selected from the group consisting of:{'sup': 1', '1', '3, 'Palladium 3-(3-sulfopropylimino)-15-methoxycarbonylmethyl-rhodobacteriochlorin 13,17-di(3-sulfopropyl)amide tripotassium salt;'}{'sup': 1', '1', '3, 'Palladium 3-(3-sulfopropylamino)-15-methoxycarbonylmethyl-rhodobacteriochlorin 13,17-di(3-sulfopropyl)amide tripotassium salt;'}{'sup': 1', '1, 'Palladium 3-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13-(3-phosphopropyl)amide tripotassium salt;'}{'sup': 1', '1', '3, 'Palladium 3-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 13,17-di(3-sulfopropyl)amide dipotassium salt; and'}{'sup': 1', '1, 'Palladium 3-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 132-carboxyethyl)amide dipotassium salt; and'}(b) irradiating local area of the tumor with an effective dose of light of appropriate wavelength,wherein the tumor is selected from melanoma, brain tumor, esophageal tumor, and bladder tumor.52. The method of claim 51 , wherein the tumor is melanoma.53. The method of claim 51 , wherein the tumor is brain tumor.54. The method of claim 51 , wherein the tumor is esophageal tumor.55. The method of claim 51 , wherein the tumor is bladder tumor.56. The method of claim 51 , wherein the compound is ...

Подробнее
20-04-2017 дата публикации

Metal-organic frameworks and process of preparing the same

Номер: US20170106348A1
Принадлежит: Korea Institute of Energy Research KIER

The present disclosure relates to a metal-organic framework and a method for preparing the same. In accordance with the present disclosure, a metal-organic framework having large specific surface area can be prepared and the prepared porous material exhibits high carbon dioxide and carbon monoxide adsorption characteristics at room temperature.

Подробнее
11-04-2019 дата публикации

MANGANESE (III) CATALYZED C--H AMINATIONS

Номер: US20190106448A1

Reactions that directly install nitrogen into C—H bonds of complex molecules are significant because of their potential to change the chemical and biological properties of a given compound. Selective intramolecular C—H amination reactions that achieve high levels of reactivity, while maintaining excellent site-selectivity and functional-group tolerance is a challenging problem. Herein is reported a manganese perchlorophthalocyanine catalyst [Mn(ClPc)] for intermolecular benzylic C—H amination of bioactive molecules and natural products that proceeds with unprecedented levels of reactivity and site-selectivity. In the presence of Brønsted or Lewis acid, the [Mn(ClPc)]-catalyzed C—H amination demonstrates unique tolerance for tertiary amine, pyridine and benzimidazole functionalities. Mechanistic studies indicate that C—H amination proceeds through an electrophilic metallonitrene intermediate via a stepwise pathway where C—H cleavage is the rate-determining step of the reaction. Collectively these mechanistic features contrast previous base-metal catalyzed C—H aminations. 3. The compound of wherein X is halo or SbF.4. The compound of wherein Ris halo.5. The compound of wherein Ris chloro.6. The compound of wherein n is 3 or 4.8. A composition comprising a compound of and a salt.9. The composition of wherein the salt is AgSbF.11. A method for forming a C—N bond comprising contacting an organic substrate claim 1 , a nitrogen-containing oxidant claim 1 , and a compound of claim 1 , in a solvent to form a mixture claim 1 , wherein a C—H moiety of the organic substrate is aminated claim 1 , thereby forming a C—N bond.12. The method of wherein the oxidant is an iminoiodinane.13. The method of wherein the iminoiodinane is formed in situ.14. The method of wherein the iminoiodinane is 2 claim 12 ,2 claim 12 ,2-trichloroethyl (phenyl-λ-iodanylidene)sulfamate.15. The method of wherein the oxidant and the compound of form a metallonitrene catalyst.16. The method of wherein the ...

Подробнее
09-04-2020 дата публикации

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Номер: US20200109124A1
Принадлежит:

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 3. The composition of claim 2 , wherein the composition is adapted for administration to a subject.4. The composition of claim 3 , wherein the composition comprises a unit dosage form of compound (3).5. The composition of claim 4 , wherein the unit dosage form delivers to the subject an amount of compound (3) between about 0.01 and about 8 mg/kg.6. The composition of claim 5 , wherein the unit dosage form delivers to the subject an amount of compound (3) of about 0.01 mg/kg claim 5 , about 0.05 mg/kg claim 5 , about 0.10 mg/kg claim 5 , about 0.20 mg/kg claim 5 , about 0.3 mg/kg claim 5 , about 0.35 mg/kg claim 5 , about 0.40 mg/kg claim 5 , about 0.45 mg/kg claim 5 , about 0.50 mg/kg claim 5 , about 0.55 mg/kg claim 5 , about 0.60 mg/kg claim 5 , about 0.65 mg/kg claim 5 , about 0.70 mg/kg claim 5 , about 0.75 mg/kg claim 5 , about 0.80 mg/kg claim 5 , about 0.90 mg/kg claim 5 , about 1 mg/kg claim 5 , about 2 claim 5 , mg/kg claim 5 , about 4 mg/kg claim 5 , about 6 mg/kg claim 5 , or about 8 mg/kg.7. The composition of claim 2 , wherein the composition is in a single dose form.8. The composition of claim 2 , wherein the composition is in dry form.9. The composition of claim 2 , wherein the composition is lyophilized in a sterile container.10. The composition of claim 2 , wherein the composition is contained within a sterile container.11. The composition of claim 10 , wherein the sterile container comprises a machine detectable identifier.12. The composition of claim 2 , further comprising one or more pharmaceutically acceptable excipients in an oral dosage form.13. The composition of claim 2 , further comprising one or more pharmaceutically acceptable carriers in an injectable dosage form.14. The composition of claim 2 , further ...

Подробнее
04-05-2017 дата публикации

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20170121287A1
Принадлежит:

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands. 1. A metal coordinating ligand having a formula{'sub': 1', '2', 'x', 'y', '7', '8', '1-6', '2-4', '1', '2', '7', '8', '3', '4', '5', '6, 'a) RRN—(CR)—N—(CR)—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl and x and y are independently 2-6, provided that when each of R, R, Rand Ris ethyl, at least one of R, R, Rand Ris not H;'}{'sub': 1', '2', '1', '2', '3', '4', '1-6', '2-4', '1', '2', '1', '2', '3', '4, 'b) RRN—Ar—NH—Ar—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Arand Arare aromatic hydrocarbon moieties which may be the same or different, provided that at least one of R, R, Rand Ris not methyl;'}{'sub': Ar1', '1', '2', 'x', '5', '3', '4', 'y', 'Ar2', '1-6', '2-4', 'Ar1', 'Ar2, 'c) N—(CRR)—NR—(CRR)—N, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Nand Nmay be the same or different and are heterocyclic aromatic moieties wherein the heteroatom is N.'}3. The metal coordinating ligand of claim 2 , wherein R claim 2 , R claim 2 , Rand Rof formula I are each ethyl (Et) and each of R-Ris independently hydrogen claim 2 , Calkyl claim 2 , acyl claim 2 , aldehyde claim 2 , keto or Calkenyl.4. A metal coordination complex comprising a transition metal ion or a boron group ion M complexed with the metal coordinating ligand of .9. The metal coordination complex of claim 8 , wherein L is one or more of halogen claim 8 , alkyl claim 8 , amino and methylamino.10. The metal coordination complex of claim 8 , wherein L is an NNN ligand.11. The metal coordination complex of claim 4 , wherein the transition metal ion or the boron group ion is selected from the group ...

Подробнее
24-07-2014 дата публикации

Iridium Containing Hydrosilylation Catalysts and Compositions Containing the Catalysts

Номер: US20140206869A1
Принадлежит: Dow Corning Corp

A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable, of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Подробнее
27-05-2021 дата публикации

Rhenium Complexes and Methods of Use

Номер: US20210155646A1
Принадлежит:

Halide ligand free rhenium complexes are described as well as methods for depositing rhenium-containing films. Some embodiments provide a rhenium complex with a general formula of OReO-M-R1R2R3, where M is a group IV element, R1 is selected from H, alkyl, alkenyl, alkynyl, an aromatic ring, or alkoxy, and R2 and R3 are each independently selected from H, alkyl, alkenyl, alkynyl, an aromatic ring, or alkoxy, or R2 and R3 join together to form a ring structure or an oxo group. Some embodiments provide a rhenium complex with a general formula of Re(NR′)(NHR″), where R′ and R″ are independently selected from H, alkyl, alkenyl, alkynyl, or an aromatic ring. 1. A rhenium complex having a general formula of OReO-M-R1R2R3 , wherein:M is a group IV element;R1 is selected from H, alkyl, aryl, and alkoxy; andR2 and R3 are each independently selected from H, alkyl, aryl, and alkoxy, or R2 and R3 join together to form a ring structure, or R2 and R3 combine to be an oxo group, provided that:{'sub': '3', 'when M is C, R1, R2 and R3 are not each H or —CH;'}{'sub': 3', '2', '5, 'when M is Si, R1, R2 and R3 are not each —CHor —CH;'}{'sub': 3', '2', '5', '6', '5, 'when M is Ge, R1, R2 and R3 are not each —CH, —CH, or —CH; and'}{'sub': 3', '2', '5', '6', '5, 'when M is Sn, R1, R2 and R3 are not each —CH, —CH, or —CH.'}2. The rhenium complex of claim 1 , wherein the group IV element is carbon.3. The rhenium complex of claim 1 , wherein the group IV element is silicon.4. The rhenium complex of claim 1 , wherein the group IV element is germanium.5. The rhenium complex of claim 1 , wherein the group IV element is tin.6. The rhenium complex of claim 1 , wherein one or more of R1 claim 1 , R2 or R3 contain a heteroatom.7. The rhenium complex of claim 1 , wherein R1 claim 1 , R2 and R3 are each independently selected from H claim 1 , alkyl claim 1 , alkenyl claim 1 , alynyl claim 1 , an aromatic ring claim 1 , or alkoxy.8. The rhenium complex of claim 1 , wherein R2 and R3 join together to ...

Подробнее
09-05-2019 дата публикации

CATALYSTS

Номер: US20190134619A1
Принадлежит:

The present invention concerns the synthesis of dry powdered manganese complexes using spray-drying or freeze-drying methods. 134-. (canceled)36. The powder of claim 35 , wherein the powder comprises less than 12 wt % water.37. The powder of claim 35 , wherein the powder comprises less than 10 wt % water.38. The powder of claim 35 , wherein the powder comprises less than 6 wt % water.39. The powder of claim 35 , wherein the inert salt is NaCl.40. The powder of claim 39 , which comprises between 25 and 75 wt % NaCl.41. The powder of claim 35 , wherein the ligand of the catalyst is selected from the group consisting of 1 claim 35 ,4 claim 35 ,7-trimethyl-1 claim 35 ,4 claim 35 ,7-triazacyclononane (Me-TACN) and 1 claim 35 ,2-bis-(4 claim 35 ,7-dimethyl-1 claim 35 ,4 claim 35 ,7-triazacyclonon-1-yl)-ethane (Me-DTNE).42. The powder of claim 35 , wherein the catalyst is a salt of the metal complexes [(Mn)(μ-O)(Me-TACN)] claim 35 , [(Mn)(μ-O)(μ-CHCOO)(Me-TACN))] or [MnMn(μ-O)(μ-CHCOO)(Me-DTNE)].43. The powder of claim 35 , wherein the catalyst has a non-coordinating counterion selected to provide a preformed transition-metal catalyst that has a water solubility of at least 30 g/l at 20° C.44. (canceled)45. The powder of claim 35 , wherein the catalyst is selected from the group consisting of [(Mn)(μ-O)(Me-TACN)]SO claim 35 , [MnMn(μ-O)(μ-CHCOO)(Me-DTNE)]Cl claim 35 , [(Mn)(μ-O)(Me-TACN)](CHCOO) claim 35 , [(Mn)(μ-O)(Me-TACN)](NO)and [MnMn(μ-O)(μ-CHCOO)(Me-DTNE)](NO).4647-. (canceled)49. The method of claim 48 , wherein the powder comprises less than 12 wt % water.50. (canceled)51. The method of claim 48 , wherein the method further comprises a synthesis of the catalyst claim 48 , prior to the spray-drying or freeze-drying claim 48 , in which a complexation between manganese ion(s) and the ligand of formula (I) is effected in a complexation mixture comprising more than 6 wt % of water.5253-. (canceled)54. The method of claim 48 , wherein the ligand is selected from the ...

Подробнее
10-06-2021 дата публикации

WRAPPING PEROVSKITE GRAINS WITH SILICA SHELLS FOR IMPROVED STABILITY AND EFFICIENCY OF PEROVSKITE ELECTRONIC DEVICES

Номер: US20210171557A1
Автор: Bai Yang, Huang Jinsong
Принадлежит:

Systems and methods for enhancing the stability and efficiency of perovskite materials, and devices incorporating such perovskite materials. A method of making a perovskite layer includes mixing a perovskite solution with a silica shell precursor solution to produce a perovskite-silica precursor solution, and spin casting or drop casting the perovskite-silica precursor solution on a substrate to form a perovskite material or material layer, wherein the perovskite material or material layer includes a plurality of groups of one or more perovskite grains, each of said plurality of groups wrapped in a silica shell. The silica shell precursor solution may have a chemical structure of R—Si—(OR), where “R” is an alkyl, aryl, or organofunctional group, and “OR” is a methoxy, ethoxy, or acetoxy group. 1. A method of forming a perovskite layer , the method comprising:mixing a perovskite solution with a silica shell precursor solution to produce a perovskite-silica precursor solution; andspin casting or drop casting the perovskite-silica precursor solution on a substrate to form a perovskite layer, wherein the perovskite layer includes a plurality of groups of one or more perovskite grains, each of said plurality of groups wrapped in a silica shell.2. The method of claim 1 , wherein the silica shell precursor solution has a chemical structure of Rn-Si—(OR)-n claim 1 , where “R” is an alkyl claim 1 , aryl claim 1 , or organofunctional group claim 1 , and “OR” is a methoxy claim 1 , ethoxy claim 1 , or acetoxy group.3. The method of claim 1 , wherein the silica shell precursor is selected from the group consisting of tetraethoxysilane (TEOS) claim 1 , tetramethoxysilane (TMOS) claim 1 , Tetrapropyl orthosilicate claim 1 , organoalkoxysilanes claim 1 , 3-(trimethoxysilyl)propylmethacrylate (TMSPMA) claim 1 , 3-glycidoxypropyltrimethoxysilane (GLYMO) claim 1 , methyltrimethoxysilane (MTMOS) claim 1 , (3-Glycidyloxypropyl)trimethoxysilane claim 1 , (3-Mercaptopropy) ...

Подробнее
25-05-2017 дата публикации

Water soluble anionic bacteriochlorophyll derivatives and their uses

Номер: US20170143988A1
Принадлежит: Yeda Research and Development Co Ltd

The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<−>, COS<−>, SO3<−>, PO3<2−>, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

Подробнее
02-06-2016 дата публикации

METAL AMIDES OF CYCLIC AMINES

Номер: US20160152649A1
Автор: GORDON Roy Gerald
Принадлежит:

Compounds, and oligomers of the compounds, are synthesized with cyclic amine ligands attached to a metal atom. These compounds are useful for the synthesis of materials containing metals. Examples include pure metals, metal alloys, metal oxides, metal nitrides, metal phosphides, metal sulfides, metal selenides, metal tellurides, metal borides, metal carbides, metal silicides and metal germanides. Techniques for materials synthesis include vapor deposition (chemical vapor deposition and atomic layer deposition), liquid solution methods (sol-gel and precipitation) and solid-state pyrolysis. Suitable applications include electrical interconnects in microelectronics and magnetoresistant layers in magnetic information storage devices. The films have very uniform thickness and high step coverage in narrow holes. 1. A composition comprising{'sub': x', 'y, 'a compound represented by the formula MAor an oligomer thereof; and'}wherein M is a metal;A is a cyclic amine ligand bonded to said M; andx and y are positive integers;wherein said metal M is selected from the group consisting of manganese, iron, cobalt, nickel, zinc, chromium, vanadium, titanium, magnesium, calcium, strontium, barium, tellurium, cadmium, tin, lead, palladium, platinum, rhodium, ruthenium, osmium, iridium, molybdenum, tungsten, niobium, tantalum, aluminum, gallium, scandium, antimony, indium, lutetium, ytterbium, thulium, erbium, thallium, yttrium, holmium, dysprosium, terbium, gadolinium, europium, samarium, neodymium, praseodymium, cerium, bismuth, and uranium.3. The composition of claim 2 , wherein the metal is selected from manganese claim 2 , iron claim 2 , cobalt claim 2 , nickel claim 2 , chromium claim 2 , vanadium claim 2 , titanium claim 2 , magnesium claim 2 , calcium claim 2 , strontium claim 2 , barium claim 2 , cadmium claim 2 , zinc claim 2 , tin claim 2 , lead claim 2 , tellurium claim 2 , europium claim 2 , palladium claim 2 , platinum claim 2 , rhodium claim 2 , ruthenium claim 2 , ...

Подробнее
02-06-2016 дата публикации

THERMALLY STABLE VOLATILE PRECURSORS

Номер: US20160152650A1
Принадлежит:

A method of forming a thin film on a substrate which includes a step of contacting a surface with a precursor compound having a transition metal and one or more alkyl-1,3-diazabutadiene ligands is provided. The resulting modified surface is then contacted with an activating compound. 2. The method of wherein the activating compound is a reducing agent and the thin film is a metallic film.3. The method of wherein the reducing agent is selected from the group consisting of molecular hydrogen claim 2 , atomic hydrogen claim 2 , silane claim 2 , disilane claim 2 , organosilanes claim 2 , compounds containing Si—H bonds claim 2 , germane claim 2 , organogermanes claim 2 , compounds containing Ge—H bonds claim 2 , stannane claim 2 , compounds containing Sn—H bonds claim 2 , other metal hydride compounds claim 2 , formic acid claim 2 , glyoxalic acid claim 2 , oxalic acid claim 2 , other carboxylic acids claim 2 , diborane claim 2 , compounds containing B—H bonds claim 2 , hydrazine claim 2 , carbon-substituted hydrazines claim 2 , formalin claim 2 , formaldehyde claim 2 , organic alcohols claim 2 , organoaluminum compounds claim 2 , organozinc compounds claim 2 , and plasma-activated versions thereof.4. The method of wherein the activating compound is an oxidizing agent and the thin film is a metal oxide.5. The method of wherein the oxidizing agent is selected from the group consisting of water claim 4 , ozone claim 4 , molecular oxygen claim 4 , atomic oxygen claim 4 , organic alcohols claim 4 , hydrogen peroxide claim 4 , organic hydroperoxides claim 4 , organic peroxides claim 4 , nitrous oxide claim 4 , and plasma-activated versions of thereof.6. The method of wherein the activating compound is a nitrogen-containing agent and the thin film is a metal nitride.7. The method of wherein the nitrogen activating compound is selected from the group consisting of ammonia claim 6 , hydrazine claim 6 , alkyl-substituted hydrazines claim 6 , and plasma activated versions thereof ...

Подробнее
21-08-2014 дата публикации

Molybdenum Containing Hydrosilylation Reaction Catalysts and Compositions Containing the Catalysts

Номер: US20140231703A1
Принадлежит: Dow Corning Corp

A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition ′ capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand.

Подробнее
16-05-2019 дата публикации

MANGANESE (II) COMPLEX, PREPARATION METHOD THEREOF, AND USE THEREOF IN ORGANIC LIGHT EMITTING DIODES

Номер: US20190144478A1
Принадлежит:

The invention relates to a manganese (II) complex, its preparation method and use. The structure of the complex is (R1R2R3R4A)2[MnX4], wherein R1, R2, R3 and R4 are identical or different, independently selected from alkyl, aryl, or heteroaryl; said alkyl, aryl, or heteroaryl can be optionally substituted with a substituent, and the substituent is preferably alkyl, aryl or heteroaryl; A is N, P, or As; X is optionally F, Cl, Br, or I. The present invention also relates to an organic light emitting diode, its preparation method and use, wherein the manganese (II) complex of the invention is used as a dopant in the light-emitting layer. The prepared organic light emitting diode exhibits high electrical-to-optical conversion efficiency which can be used for flat-panel displays and illuminations. 1. A manganese (II) complex , wherein chemical structure of the manganese (II) complex is (RRRRA)[MnX] ,{'sub': 1', '2', '3', '4', '1', '2', '3', '4, 'wherein R, R, Rand Rare identical or different, and R, R, Rand Rare independently selected from alkyl, aryl, or heteroaryl; the alkyl, the aryl, or the heteroaryl may be optionally substituted with a substituent, and the substituent is preferably an alkyl group, an aryl group or a heteroaryl group;'}A is N, P, or As;X is optionally F, Cl, Br, or I;{'sub': 1', '2', '3', '4, 'wherein, when A is N, R, R, Rand Rcannot be a butyl simultaneously;'}the alkyl is a linear or branched alkyl having 1 to 10 carbon atoms; the aryl is a monocyclic or polycyclic aromatic group having 6 to 20 carbon atoms; the heteroaryl is a monocyclic or polycyclic heteroaromatic group having 1 to 20 carbon atoms containing at least one heteroatoms selected from N, S or O.4. A method for preparing the manganese (II) complex according to , comprising the following steps: mixing MnXand (RRRRA)X in a solvent to obtain the manganese (II) complex , wherein R , R , R , R , A and X are defined according to ; the solvent is preferably alcohol or halogenated ...

Подробнее
11-06-2015 дата публикации

ANTIBACTERIAL MICROELEMENT CHELATES AND THE USE THEREOF IN ANIMAL FEEDS

Номер: US20150157594A1
Принадлежит: Dr. Bata Zrt.

The present invention relates to a microelement organic O-chelate or N-chelate complex compound, for the inhibition of facultative pathogenic bacteria. The present invention further relates to a composition, feed additive or feed comprising the compounds, as well as methods for the preparation thereof, and for the use thereof in animal stock farming. 1. Microelement organic chelate complex compound , for the inhibition of pathogenic bacteria , having the general formula{'br': None, 'sub': n', 'm', 'o, '(M)(X)(Y)'}wherein M is Zn, Cu, Fe, Mn, Ag;{'sub': 4', '2, 'X is NH, HO;'}Y is an amino acid (preferably selected from the group consisting of the 20 naturally occurring amino acids), a fatty acid (preferably formic acid, acetic acid or propionic acid), hydroxy acid (preferably maleic acid or lactic acid) and/or polyamino-carboxylic acid (preferably nitrilotriacetic acid or ethylenediamine tetraacetic acid);n is 0-6;m is 1-6;o is 1-8.2Salmonella, E. coli, ClostridiumBrachyspyraArcanobacteriumStaphylococcusStreptococcusLawsoniaEimerella. The compound according to claim 1 , wherein the facultative pathogenic bacterium is selected from the group consisting of: sp. claim 1 , sp. claim 1 , sp. claim 1 , sp. claim 1 , sp. claim 1 , sp. claim 1 , sp.3Salmonella enterica, Salmonella entericaEnterica serovar enteritidis, Salmonella typhimurium, Salmonella infantis, Salmonella gallinarium, S. paratyphi, S. abortusequi, S. java, S. cholerae, S. typhisuis, S. sendai, Escherichia coli, Clostridium perfringens, Cl. barati, Cl. sordellii. Cl. botulinum AF, Cl., novyy A, B, C, D, Cl. septicum, Cl. chuvoei, Cl. hystoliticum, Cl. sporogenes, Cl. tetani, Brachyspira hyodysenteriaea, Brachyspira pilosicoli Arcanobacterium piogenes, Staphylococcus aureus, Streptococcus agalactiae, Lawsonia intracellularis.. The compound according to claim 2 , wherein the pathogenic bacterium is selected from the group consisting of: subp. ---4. A method for the treatment or prevention of a disease ...

Подробнее
14-05-2020 дата публикации

DIMETHYLAMMONIUM-CONTAINING PEROVSKITE DEVICES

Номер: US20200148711A1
Принадлежит:

The present disclosure relates to a perovskite that includes ABX, where A is an organic cation, B is a second cation, X is an anion, and the perovskite has a film density (ρ) of less than 4.37 g/cm. In some embodiments of the present disclosure, the film density may be in the range, 4.1 g/cm≤ρ≤4.37 g/cm. In some embodiments of the present disclosure, the organic cation may include at least one of dimethylammonium (DMA), guanidinium (GA), and/or acetamidinium (Ac). In some embodiments of the present disclosure, A may further include cesium. 1. A perovskite comprising ABX , wherein:A comprises an organic cation,B comprises a second cation,X comprises an anion, and{'sup': '3', 'the perovskite has a film density (ρ) of less than 4.37 g/cm.'}2. The perovskite of claim 1 , wherein 4.1 g/cm≤ρ≤4.37 g/cm.3. The perovskite of claim 1 , wherein the organic cation comprises at least one of dimethylammonium (DMA) claim 1 , guanidinium (GA) claim 1 , or acetamidinium (Ac).4. The perovskite of claim 3 , wherein A further comprises cesium.5. The perovskite of claim 4 , comprising DMACsBX claim 4 , wherein 0≤x≤0.8.6. The perovskite of claim 5 , wherein A further comprises formamidinium (FA).7. The perovskite of claim 6 , comprising DMACsFABX claim 6 , wherein 0.40≤y≤0.90.8. The perovskite of claim 1 , wherein B comprises at least one of lead or tin.9. The perovskite of claim 8 , comprising DMACsFAPbX.10. The perovskite of claim 1 , wherein the anion comprises at least one of chlorine claim 1 , bromine claim 1 , or iodine.11. The perovskite of claim 10 , comprising DMACsFAPbICl claim 10 , wherein 0 Подробнее

24-06-2021 дата публикации

Platinum compounds for binding guanine quadruplexes

Номер: US20210188889A1

Compounds are described and characterized that bind guanine quadruplexes of DNA or RNA. Binding data and inhibition of growth data of five cancer cell lines are presented.

Подробнее
16-06-2016 дата публикации

CHROMIUM(III) SILICATE CATALYSTS SUITABLE FOR PE SYNTHESIS

Номер: US20160168283A1
Принадлежит:

Molecular precursor chromium compounds and chromium on silica catalyst precursors suitable for sure in producing chromium on silica catalysts are disclosed. The molecular precursor compounds can be chromium(II) and/or chromium(III) and/or chromium (IV) compounds wherein all ligands are easily removable, in particular ligands selected from the group consisting of anionic ligands of the type —O—CRR—CH—R—Ror —O—Si—(O—CRR—CH—RR)wherein R1, R2, R3 and R4 may be the same or different and may be any group that does not affect decomposition of the ligand via elimination of beta-hydrogen from —CRR—CH—RR, amide anionic ligands of the type —N—Si—RRRand/or —N—C—RRR, wherein R, Rand Rcan be the same or different and are preferably selected from hydrogen, methyl groups, ethyl groups, n-propyl groups, iso-propyl groups, tert-butyl groups or aromatic groups; as well as coordinating solvents. These molecular precursors can be grafted to silica and—if need be—either before or after heat treatment during which the ligands are removed, oxidized to Cr(III). The chromium on silica catalyst is characterized by the absence of any organic ligands. 118.-. (canceled)19. Use of a molecular precursor chromium compound for producing a chromium (III) on silica catalyst , said molecular precursor compound being a chromium(II) and/or a chromium(III) and/or a chromium (IV) compound wherein all ligands are easily removable , in particular ligands selected from the group consisting of anionic ligands of the type —O—CRR—CH—RRor —O—Si—(O—CRR—CHRR)wherein R1 , R2 , R3 and R4 may be the same or different and may be any group that does not affect decomposition of the ligand via elimination of beta-hydrogen from —CRR—CH—RR , and amide anionic ligands of the type —N—(Si—RRR)and/or —N—(C—RRR)wherein R , Rand Rcan be the same or different and are preferably selected from hydrogen , methyl groups , ethyl groups , n-propyl groups , iso-propyl groups , tert-butyl groups or aromatic groups; as well as coordinating ...

Подробнее
14-06-2018 дата публикации

CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING

Номер: US20180162784A1
Принадлежит:

Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections. 25-. (canceled)6. A conjugate comprising: a non-steroidal anti-inflammatory drug (NSAID) , a residue of a NSAID , or a derivative of a NSAID bonded or complexed to an imaging moiety which comprises a radioactive agent , wherein the radioactive agent is selected from the group consisting of a gamma-ray emitter , an X-ray emitter , and a beta emitter; or a pharmaceutically acceptable salt thereof , wherein the non-steroidal anti-inflammatory drug (NSAID) , residue of a NSAID , or derivative of a NSAID is celecoxib , a residue of celecoxib , or a derivative of celecoxib.7. The conjugate of claim 6 , wherein said radioactive agent is Tc claim 6 , Mn claim 6 , Re or Re.8. The conjugate of claim 7 , wherein the imaging moiety further comprises a chelating group which bonds or complexes to the radioactive agent; and where the imaging moiety is optionally bonded to the non-steroidal anti-inflammatory drug (NSAID) claim 7 , residue of a NSAID claim 7 , or derivative of a NSAID via a linker.10. The conjugate of claim 8 , wherein the NSAID claim 8 , residue of an NSAID claim 8 , or derivative of a NSAID and the imaging moiety are bonded or complexed via a linker claim 8 , wherein the linker is ...

Подробнее
23-06-2016 дата публикации

FIRST-ROW TRANSITION METAL HYDROGENATION AND HYDROSILYLATION CATALYSTS

Номер: US20160176908A1
Принадлежит:

Transition metal compounds, and specifically transition metal compounds having a tetradentate and/or pentadentate supporting ligand are described, together with methods for the preparation thereof and the use of such compounds as hydrogenation and/or hydrosilylation catalysts. 4. The metal complex of claim 1 , wherein:M is Mn, Fe, Co, or Ni; and{'sub': 2', '2, 'each X is independently selected from PR, NR, and any other donor group.'}5. The metal complex of claim 3 , wherein Z is hydride.6. A catalytic composition comprising the metal complex of .7. A method for reducing one or more organic substrates comprising contacting a composition comprising one or more organic substrates with a catalytic composition comprising a metal complex according to in the presence of a reductant claim 1 , whereby the one or more organic substrates are reduced.8. The method of claim 8 , wherein the reductant is a silane claim 8 , a substituted silane claim 8 , an alkoxysilane claim 8 , hydrogen claim 8 , a substituted borane claim 8 , a substituted alane claim 8 , or a mixture thereof.9. The method of claim 7 , wherein the one or more organic substrates contain a ketone claim 7 , an ester claim 7 , or mixtures thereof.10. The method of claim 9 , wherein the one or more organic substrates include an unsaturated organic compound.11. The method of claim 10 , wherein the unsaturated organic compound is an olefin or an alkyne.12. A method of facilitating a hydrosilylation reaction claim 1 , comprising reacting a compound comprising an Si—H bond with an unsaturated organic compound in the presence of one or more of the metal complexes of .13. The method of claim 12 , whereby the Si and H atoms in the Si—H bond are added across an unsaturated bond in the unsaturated organic compound to form an organosilicon compound.14. A method of facilitating a hydrogenation reaction claim 1 , comprising reacting Hwith an unsaturated organic compound in the presence of one or more of the metal complexes of . ...

Подробнее
06-06-2019 дата публикации

CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGING

Номер: US20190169084A1
Принадлежит:

Conjugates derived from non-steroidal anti-inflammatory drugs (NSAIDs) and methods of use thereof are disclosed, useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The NSAID-based conjugates contain an imaging moiety. The conjugates concentrate at sites of increased cyclooxygenase expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections. 25-. (canceled)6. A conjugate comprising: a non-steroidal anti-inflammatory drug (NSAID) , a residue of a NSAID , or a derivative of a NSAID bonded or complexed to an imaging moiety which comprises a radioactive agent , wherein the radioactive agent is selected from the group consisting of a gamma-ray emitter , an X-ray emitter , and a beta emitter; or a pharmaceutically acceptable salt thereof.7. The conjugate of claim 6 , wherein said radioactive agent is Tc claim 6 , Mn claim 6 , Re or Re.8. The conjugate of claim 7 , wherein the imaging moiety further comprises a chelating group which bonds or complexes to the radioactive agent; and where the imaging moiety is optionally bonded to the non-steroidal anti-inflammatory drug (NSAID) claim 7 , residue of a NSAID claim 7 , or derivative of a NSAID via a linker.10. The conjugate of claim 8 , wherein the NSAID claim 8 , residue of an NSAID claim 8 , or derivative of a NSAID and the imaging moiety are bonded or complexed via a linker claim 8 , wherein the linker is selected from the group consisting of:{'sub': 1', '10, 'an optionally substituted C-Chydrocarbylene group;'}{'sub': 2', '10, 'an optionally substituted C-Cheterohydrocarbylene ...

Подробнее
30-06-2016 дата публикации

Manganese Complexes And Use Thereof For Preparing Thin Films

Номер: US20160185807A1
Принадлежит:

Manganese complexes, methods of making the same, and use thereof in thin film deposition, such as CVD and ALD are provided herein. 2. The manganese complex of or a solvate thereof claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare independently selected from the group consisting of hydrogen claim 1 , CC-alkyl claim 1 , and tri(CC-alkyl)silyl.3. The manganese complex of claim 1 , or a solvate thereof claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare independently selected from the group consisting of hydrogen claim 1 , methyl claim 1 , ethyl claim 1 , n-propyl claim 1 , isopropyl claim 1 , n-butyl claim 1 , isobutyl claim 1 , tert-butyl claim 1 , n-pentyl claim 1 , neopentyl claim 1 , n-hexyl claim 1 , n-heptyl claim 1 , n-octyl claim 1 , trimethylsilyl claim 1 , triethylsilyl claim 1 , triisopropylsilyl claim 1 , and tert-butyldimethylsilyl.5. The manganese complex of or a solvate thereof claim 4 , wherein R claim 4 , R claim 4 , and Rare independently hydrogen or CC-alkyl.8. The manganese complex of or a solvate thereof claim 7 , wherein R claim 7 , R claim 7 , R claim 7 , R claim 7 , and Rare independently selected from the group consisting of hydrogen claim 7 , C-C-alkyl claim 7 , and tri(CC-alkyl)silyl.9. The manganese complex of claim 7 , or a solvate thereof claim 7 , wherein R claim 7 , R claim 7 , R claim 7 , R claim 7 , and Rare independently selected from the group consisting of hydrogen claim 7 , methyl claim 7 , ethyl claim 7 , n-propyl claim 7 , isopropyl claim 7 , n-butyl claim 7 , isobutyl claim 7 , tert-butyl claim 7 , n-pentyl claim 7 , neopentyl claim 7 , n-hexyl claim 7 , n-heptyl claim 7 , n-octyl claim 7 , trimethylsilyl claim 7 , triethylsilyl claim 7 , triisopropylsilyl claim 7 , and tert-butyldimethylsilyl.11. The manganese complex of or a solvate thereof claim 10 , wherein R claim 10 , R claim 10 , and Rare independently hydrogen or C-C-alkyl.13. The manganese complex of or a solvate thereof ...

Подробнее
20-06-2019 дата публикации

DIAZADIENYL COMPOUND, RAW MATERIAL FOR FORMING THIN FILM, AND METHOD FOR MANUFACTURING THIN FILM

Номер: US20190185994A1
Принадлежит: ADEKA CORPORATION

A diazadienyl compound represented by General Formula (I) below: 14-. (canceled)6. The raw material for forming a thin film according to claim 5 , wherein Rin General Formula (I) is a methyl group.7. A method for manufacturing a thin film claim 5 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00005', 'claim 5'}, 'introducing a vapor including a diazadienyl compound obtained by vaporizing the raw material for forming a thin film according to and a reactive gas into a film formation chamber in which a substrate is disposed; and'}forming, on a surface of the substrate, a thin film including at least one atom selected from nickel atom and manganese atom by inducing decomposition and/or chemical reaction of the diazadienyl compound.8. The method for manufacturing a thin film according to claim 7 , wherein the reactive gas is hydrogen.9. A method for manufacturing a thin film claim 7 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00006', 'claim 6'}, 'introducing a vapor including a diazadienyl compound obtained by vaporizing the raw material for forming a thin film according to and a reactive gas into a film formation chamber in which a substrate is disposed; and'}forming, on a surface of the substrate, a thin film including at least one atom selected from nickel atom and manganese atom by inducing decomposition and/or chemical reaction of the diazadienyl compound.10. The method for manufacturing a thin film according to claim 9 , wherein the reactive gas is hydrogen. The present invention relates to a novel diazadienyl compound, a raw material for forming a thin film that includes the compound, and a method for manufacturing a thin film by using the raw material for forming a thin film.Thin-film materials including a metal element have been used for a variety of applications because such materials exhibit electric properties, optical properties and the like. For example, nickel and nickel-containing thin films are mainly used for parts of electronic ...

Подробнее
18-06-2020 дата публикации

MANUFACTURING OF PEROVSKITE FILMS

Номер: US20200189927A1
Принадлежит:

The present disclosure relates to a mixture that includes a perovskite precursor, a solvent, and an additive that includes at least one of a first amine, a ketone, an aldehyde, a non-nucleophilic sterically hindered base, and/or a halogen-containing compound, where, upon removal of the solvent and the additive, the perovskite precursor is capable of being transformed into a perovskite. 1. A mixture comprising:a perovskite precursor;a solvent; andan additive comprising at least one of a first amine, a ketone, an aldehyde, a non-nucleophilic sterically hindered base, or a halogen-containing compound, wherein:upon removal of the solvent and the additive, the perovskite precursor is capable of being transformed into a perovskite.2. The mixture of claim 1 , wherein the additive is present at a first concentration relative to the solvent between greater than 0 v/v and less than or equal to 20% v/v.3. The mixture of claim 1 , wherein:{'sub': '3', 'the perovskite has a stoichiometry of ABX,'}A is a first cation,B is a second cation, andX is an anion.4. The mixture of claim 1 , wherein the perovskite precursor comprises at least one of methylammonium chloride (MACl) claim 1 , methylammonium bromide (MABr) claim 1 , methylammonium iodide (MAI) claim 1 , formamidinium chloride (FACl) claim 1 , formamidinium bromide (FABr) claim 1 , formamidinium iodide (FAI) claim 1 , lead iodide (PbI) claim 1 , tin iodide claim 1 , cesium chloride claim 1 , cesium bromide claim 1 , or cesium iodide.5. The mixture of claim 1 , wherein the ketone comprises at least one of 4 claim 1 ,4-dimethyl-2-pentanone claim 1 , acetone claim 1 , 2-heptanone claim 1 , or 2 claim 1 ,4-dimethyl-3-pentanone.6. The mixture of claim 1 , wherein the aldehyde comprises at least one of acetaldehyde or benzaldehyde.7. The mixture of claim 1 , wherein the non-nucleophilic sterically hindered base comprises at least one of diisopropylethylamine claim 1 , triethylamine claim 1 , 2 claim 1 ,6-di-t-butylpyridine claim 1 , ...

Подробнее
29-07-2021 дата публикации

Detergent Composition With Catechol Metal Complex Compound

Номер: US20210230513A1
Принадлежит:

Catechol metal complex compounds of formula (I) 2. The detergent according to wherein claim 1 , in formula (I) the groups Rand Rindependently represent an alkyl group claim 1 , an alkoxyalkyl group claim 1 , a hydroxyalkyl group claim 1 , a hydroxyalkyloxyalkyl group claim 1 , (N-hydroxyethyl)-aminoethyl claim 1 , (N-methoxyethyl)-aminoethyl or (N-ethoxyethyl)-aminoethyl claim 1 , or an aromatic group.3. The detergent according to wherein claim 1 , in formula (I) the groups Rand Rare the same.4. The detergent according to wherein claim 1 , in formula (I) M is selected from Fe claim 1 , Mn claim 1 , Cr claim 1 , Ni claim 1 , Co claim 1 , Ce claim 1 , Cu or hydrates of these metal ions.5. The detergent according to claim 1 , wherein the detergent has a pH at 20° C. from 6 to 11.5.6. The detergent according to claim 1 , wherein at least one anionic surfactant and/or at least one non-ionic surfactant is contained.7. The detergent according to claim 1 , wherein the catechol metal complex compound of formula (I) absorbs light in a wavelength from 400 to 800 nm claim 1 , measured by means of a two-beam spectrophotometer at a concentration of the complex of 10mol/L in water at 20° C. claim 1 , a pH of 8 and a layer thickness of 1 cm.9. The detergent according to claim 8 , wherein it contains the free catechol compound of formula (II) in a total amount from 0.01 to 10.0 wt. %.10. A multi-component detergent claim 1 , wherein at least one component is a detergent according to and at least one further additional component is selected from at least one composition selected from a liquid composition or a powder composition or granules.11. The multi-component detergent according to claim 10 , wherein the multi-component detergent is in the form of a multi-chamber pouch.12. The multi-component detergent according to claim 10 , wherein the multi-component detergent contains a bitter principle claim 10 , and the bitter principle is contained in the detergent and/or in the container ...

Подробнее
29-07-2021 дата публикации

Multi-Component Detergent Comprising Catechol Metal Complex

Номер: US20210230514A1
Принадлежит:

A multi-component detergent, including at least two components, that is contained in a container having at least two chambers, wherein a first component K1 is a first liquid composition, containing at least one catechol metal complex compound of formula (I) 2. The multi-component detergent according to wherein claim 1 , in formula (I) claim 1 , the functional groups Rand Rrepresent claim 1 , independently of one another claim 1 , an alkyl group claim 1 , an alkoxyalkyl group claim 1 , a hydroxyalkyl group claim 1 , a hydroxyalkyloxyalkyl group claim 1 , (N-hydroxyethyl)-aminoethyl claim 1 , (N-methoxyethyl)-aminoethyl or (N-ethoxyethyl)-aminoethyl claim 1 , or an aromatic group.3. The multi-component detergent according to wherein claim 1 , in formula (I) claim 1 , the functional groups Rand Rare identical.4. The multi-component detergent according to wherein claim 1 , in formula (I) claim 1 , M is selected from Fe claim 1 , Mn claim 1 , Cr claim 1 , Ni claim 1 , Co claim 1 , Ce claim 1 , Cu or hydrates of these metal ions.5. The multi-component detergent according to claim 1 , wherein the catechol metal complex compound of formula (I) absorbs light in a wavelength of 400 to 800 nm claim 1 , measured by means of a two-beam spectrophotometer at a concentration of the complex of 10mol/L in water at 20° C. claim 1 , a pH of 8 and a layer thickness of 1 cm.6. The multi-component detergent according to claim 1 , wherein the catechol metal complex compound of formula (I) is contained in component K1 from 0.001 to 10.0 wt. % based on the total weight of the first liquid composition.7. The multi-component detergent according to claim 1 , wherein the free catechol compound of formula (II) is contained in component K1 in a total amount of from 0.5 to 50 wt. % based on the total weight of the first liquid composition.8. The multi-component detergent according to claim 1 , wherein the first liquid composition of component K1 contains at least one organic solvent.9. The multi- ...

Подробнее
13-08-2015 дата публикации

Hydrosilylation Catalysts Made With Terdentate Nitrogen Ligands And Compositions Containing The Catalysts

Номер: US20150224490A1
Принадлежит:

A composition contains (A) a hydrosilylation reaction catalyst and (B) an aliphatically unsaturated compound having an average, per molecule, of one or more aliphatically unsaturated organic groups capable of undergoing hydrosilylation reaction. The composition is capable of reacting via hydrosilylation reaction to form a reaction product, such as a silane, a gum, a gel, a rubber, or a resin. Ingredient (A) contains a metal-ligand complex that can be prepared by a method including reacting a metal precursor and a ligand. 115-. (canceled)17. The method of claim 16 , further comprising (2) combining the reaction product with an activator.1827-. (canceled)29. The composition of claim 28 , where the ruthenium metal compound is bis(2-methylallyl)(1 claim 28 ,5-cyclooctadiene) ruthenium(II).30. The composition of claim 28 , where each alkyl for A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , A claim 28 , and Ais independently selected from methyl claim 28 , ethyl claim 28 , propyl claim 28 , and butyl; each monovalent hydrocarbon group for Aand Ais independently selected from alkyl claim 28 , alkenyl claim 28 , carbocyclic claim 28 , aryl claim 28 , and aralkyl; and each monovalent heteroatom containing group for Aand Ais independently selected from halogenated hydrocarbon group or a hydrocarbonoxy group.33. The composition of claim 28 , where ingredient (C) is a silane of formula RSiH claim 28 , where subscript e is 0 claim 28 , 1 claim 28 , 2 claim 28 , or 3; subscript f is 1 claim 28 , 2 claim 28 , 3 claim 28 , or 4 claim 28 , with the proviso that a sum of (e+f) is 4 claim 28 , and each Ris independently a halogen atom or a monovalent organic group.34. The composition of claim 28 , where the composition further comprises one or more additional ingredients claim 28 , which are distinct from ingredients (A) claim 28 , (B) claim 28 , and (C) claim 28 , and which ...

Подробнее
04-08-2016 дата публикации

TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF

Номер: US20160222036A1
Принадлежит: Molecular Insight Pharmaceuticals, Inc.

A method of imaging a region in a subject includes administering to the subject a complex of a metal chelated to a compound, and obtaining an image of the region in the subject. 114-. (canceled)167. A pharmaceutical formulation comprising the complex of claim and a pharmaceutically acceptable excipient.17. The complex of claim 15 , wherein the metal is a radionuclide.18. The complex of claim 15 , where in the metal is yttrium claim 15 , lutetium claim 15 , gallium claim 15 , or indium.19. A pharmaceutical formulation comprising the complex of and a pharmaceutically acceptable excipient. This application is a continuation of U.S. patent application Ser. No. 14/446,220, filed on Jul. 29, 2014, which in turn is a continuation of U.S. patent application Ser. No. 14/041,643, filed on Sep. 30, 2013, now U.S. Pat. No. 8,840,865, which in turn is a continuation of U.S. patent application Ser. No. 12/631,312, filed on Dec. 4, 2009, now U.S. Pat. No. 8,562,945, which in turn is a continuation-in-part of U.S. patent application Ser. No. 12/350,894, filed on Jan. 8, 2009, now U.S. Pat. No. 8,877,970, all of which claim the benefit of U.S. Provisional Application Nos. 61/020,043, filed on Jan. 9, 2008; 61/088,980, filed on Aug. 14, 2008; and 61/142,002, filed on Dec. 31, 2008. This application also claims the benefit of U.S. Provisional Patent Application Nos. 61/120,226, filed on Dec. 5, 2008, and 61/180,341, filed on May 21, 2009, all applications and patents of which are incorporated herein by reference in their entirety, for any and all purposes.The present technology is generally related to radiopharmaceutical agents.Radiopharmaceuticals may be used as diagnostic or therapeutic agents by virtue of the physical properties of their constituent radionuclides. Thus, their utility is not based on any pharmacologic action per se. Most clinical drugs of this class are diagnostic agents incorporating a gamma-emitting nuclide which, because of physical, metabolic or biochemical ...

Подробнее
13-08-2015 дата публикации

METAL COMPLEX AND METHOD FOR PRODUCING HYDROGEN PEROXIDE

Номер: US20150225236A1
Принадлежит:

An object of the present invention is to provide a novel method for producing hydrogen peroxide by direct synthesis that is capable of taking the place of the conventional anthraquinone process, and to provide a catalyst used in the production method. 2: The metal complex according to claim 1 , wherein the number of carbon atoms of the alkyl group is 1 to 4 claim 1 , the number of carbon atoms of the aralkyl group is 7 to 10 claim 1 , the number of carbon atoms of the aryl group is 6 to 9 claim 1 , the number of carbon atoms of the alkoxy group is 1 to 4 claim 1 , the number of carbon atoms of the aralkyloxy group is 7 to 10 claim 1 , and the number of carbon atoms of the aryloxy group is 6 to 9.3: The metal complex according to claim 1 , represented by the formula (1) claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rrepresent hydrogen atoms claim 1 , Rand Rrepresent methyl groups claim 1 , one of X claim 1 , Y and Z represents OH claim 1 , the remaining two represent HO claim 1 , and An1 represents a nitrate ion.4: The metal complex according to claim 1 , represented by the formula (2) claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rrepresent hydrogen atoms claim 1 , Rand Rrepresent methyl groups claim 1 , Y represents HO and An2 represents a nitrate ion.5: The metal complex according to claim 1 , represented by the formula (3) claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rrepresent hydrogen atoms claim 1 , Rand Rrepresent methyl groups claim 1 , Y represents HO and An3 represents a nitrate ion.6: The metal complex according to claim 1 , represented by the formula (4) claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Rand Rrepresent hydrogen atoms claim 1 , Rand Rrepresent methyl groups claim 1 , X and Y represent HO and An4 represents a nitrate ion.8: The metal complex according to claim 1 , represented by the formula (1).9: The ...

Подробнее
04-08-2016 дата публикации

CONJUGATES OF 1,4,7-TRIAZACYCLONONANES, DINUCLEAR METAL COMPLEXES OF SUCH CONJUGATES, AND METHODS OF USE FOR BOTH 1,4,7-TRIAZACYCLONONANES AND CONJUGATE

Номер: US20160223491A1
Принадлежит:

Conjugates of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes with a variety of conjugating members are used in the formation of dinuclear metal complexes which bind to phosphate esters. By virtue of their conjugated forms, the complexes are incorporated into chromatographic media, affinity binding reagents, and dyes, which make the complexes useful in a wide range of assays, separations, and purifications. In addition, dinuclear metal complexes of 1,3-bis(1,4,7-triazacyclonon-1-yl)-2-hydroxypropanes that are not so conjugated are used in the detection of phosphate esters of biological species by either MALDI-TOF mass spectrometry or by dye displacement. 139.-. (canceled)4145.-. (canceled)46. The method of wherein M is a member selected from the group consisting of Ca claim 40 , Zn claim 40 , Cr claim 40 , Mn claim 40 , Fe claim 40 , Co claim 40 , Ni claim 40 , and Cu.47. The method of wherein M is a member selected from the group consisting of Zn and Mn.48. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare independently selected from the group consisting of H and C-Calkyl.49. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare H.50. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare independently selected from the group consisting of H and C-Calkyl.51. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare H.52. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare independently selected from the group consisting of H and C-Calkyl.53. The method of wherein Ris -L-R claim 40 , and R claim 40 , R claim 40 , R claim 40 , R claim 40 , and Rare H.54. The method of wherein L is a member selected from the group consisting of —CH—C(═O)—NH—CH—CH— claim 40 , —CH—C(═O)—NH—CH—CH—NH— claim 40 , and —CH—NH ...

Подробнее
12-08-2021 дата публикации

TRANSITION METAL ORGANIC FRAMEWORK HAVING ANTIBACTERIAL PROPERTIES

Номер: US20210244030A1
Принадлежит:

The present invention relates to a transition metal organic framework, comprising: a transition metal oxide having antibacterial or antifungal properties; and an organic compound having at least one hydrophilic functional group, wherein the organic compound is bound to the transition metal oxide to surround the transition metal oxide and the hydrophilic functional group is placed toward the outside of the transition metal organic framework. 1. A transition metal organic framework comprising:a transition metal oxide having antibacterial or antifungal properties; andan organic compound bound to the transition metal oxide,wherein the organic compound surrounds the transition metal oxide by forming a coordinate covalent bond to the transition metal oxide,wherein the organic compound comprises:ligands forming the coordinate covalent bond to the transition metal oxide; andorganic brushes placed at ends of the ligands, andwherein the organic brushes each contain a hydrophilic functional group, and the hydrophilic functional group is placed toward outside of the transition metal organic framework.2. The transition metal organic framework of claim 1 , wherein a metal of the transition metal oxide includes at least one selected from a group consisting of W claim 1 , Mo claim 1 , La claim 1 , Ti claim 1 , Si claim 1 , Zr claim 1 , Re claim 1 , Hf claim 1 , Ag claim 1 , Cu claim 1 , Sn claim 1 , Nb claim 1 , Al claim 1 , and Va.3. The transition metal organic framework of claim 1 , wherein the hydrophilic functional group of the organic brush includes at least one of a carboxyl group (R—COOH) claim 1 , a ketone group (R—CO—R) or an amine group (R—NH claim 1 , R—NH claim 1 , R—N claim 1 , (R—N═R).4. The transition metal organic framework of claim 3 , wherein the organic brush includes cyclic hydrocarbon.6. The transition metal organic framework of claim 1 , wherein a content of the transition metal oxide is 0.1 to 5 wt % of the transition metal organic framework.7. The ...

Подробнее
18-07-2019 дата публикации

AMINOIODOSILANES AND METHODS OF SYNTHESIZING THESE AMINOIODOSILANES

Номер: US20190218238A1
Принадлежит:

Methods of synthesizing aminoiodosilanes are disclosed. The reaction to produce the disclosed aminoiodosilanes is represented by the formula: 1. A method of synthesizing an aminoiodosilane comprising:{'sub': 2', 'y', 'z', '1', '10, 'sup': 1', '1', '1, 'contacting an iodosilane having the formula SiI4 with an monosubstituted amine having the formula NHRto produce an aminoiodosilane reaction product having the formula SiI(NHR), wherein Ris selected from a C-Calkyl or cycloalkyl, aryl, or a hetero group; y=1 to 3; and z=4−y.'}2. The method of claim 1 , wherein a molar ratio of the iodosilane to the monosubstituted amine ranges from approximately 1:2 to 1:4.3. The method of claim 1 , further comprising isolating the aminoiodosilane reaction product from a crude mixture produced by the reaction.4. The method of claim 1 , further comprising vacuum distilling the aminoiodosilane reaction product.5. The method of claim 1 , wherein the method produces an aminoiodosilane reaction product and an alkylammoniuim iodide salt.6. The method of claim 1 , wherein the reaction is performed in a solvent.7. The method of claim 7 , wherein the solvent is toluene.8. The method of claim 1 , wherein the monosubstituted amine is t-butylamine and the aminoiodosilane is t-butylaminotriiodosilane.9. The method of claim 1 , wherein the monosubstituted amine is methylamine or ethylamine and the aminoiodosilane is methylaminotriiodosilane or ethylaminotriiodosilane.10. The method of claim 1 , wherein the monosubstituted amine is isopropylamine and the aminoiodosilane is isopropylaminotriiodosilane.11. The method of claim 1 , wherein the aminoiodosilane is bis(t-butylamino)diiodosilane or bis(isopropylamino)diiodosilane.12. The method of claim 1 , wherein the amine is added to the iodosilane.13. A method of synthesizing an aminoiodosilane comprising the steps of:adding a tetraiodosilane to a reactor;{'sup': 1', '1, 'sub': 1', '10, 'adding a monosubstituted amine having the formula, NHR, to the ...

Подробнее
09-07-2020 дата публикации

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

Номер: US20200216402A1
Принадлежит:

Compositions and methods for visualizing tissue under illumination with near-infrared radiation, including compounds comprising near-infrared, closed chain, sulfo-cyanine dyes and prostate specific membrane antigen ligands are disclosed. 5. A compound according to claim 1 , wherein Ris COH and Ris H or Ris COH and Ris H.6. A compound according to claim 1 , wherein Ris CORand Ris H or Ris COR claim 1 , and Ris H.7. A compound according to claim 1 , wherein Ris H claim 1 , and Ris H.8. A compound according to claim 1 , wherein Ris C-Caryl claim 1 , or alkylaryl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms.9. A compound according to claim 1 , wherein Ris C-Caryl.10. A compound according to wherein Ris phenyl.11. A compound according to claim 1 , wherein FG is a fluorescent dye moiety which emits in the near infrared spectrum.12. A compound according to claim 1 , wherein FG comprises carbocyanine claim 1 , indocarbocyanine claim 1 , oxacarbocyanine claim 1 , thiacarbocyanine and merocyanine claim 1 , polymethine claim 1 , coumarine claim 1 , rhodamine claim 1 , xanthene claim 1 , fluorescein claim 1 , boron-dipyrromethane (BODIPY) claim 1 , Cy5 claim 1 , Cy5.5 claim 1 , Cy7 claim 1 , VivoTag-680 claim 1 , VivoTag-S680 claim 1 , VivoTag-S750 claim 1 , AlexaFluor660 claim 1 , AlexaFluor680 claim 1 , AlexaFluor700 claim 1 , AlexaFluor750 claim 1 , AlexaFluor790 claim 1 , Dy677 claim 1 , Dy676 claim 1 , Dy682 claim 1 , Dy752 claim 1 , Dy780 claim 1 , DyLight547 claim 1 , Dylight647 claim 1 , HiLyte Fluor 647 claim 1 , HiLyte Fluor 680 claim 1 , HiLyte Fluor 750 claim 1 , IRDye 800CW claim 1 , IRDye 800RS claim 1 , IRDye 700DX claim 1 , ADS780WS claim 1 , ADS830WS claim 1 , and ADS832WS.15. A method of imaging one or more cells claim 1 , organs or tissues by exposing the cell to or administering to an organism an effective amount of a compound according to claim 1 , where the compound includes a fluorescent dye moiety suitable for imaging.16 ...

Подробнее
27-08-2015 дата публикации

WATER SOLUBLE ANIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND THEIR USES

Номер: US20150238773A1
Принадлежит:

The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO<->, COS<->, SO3<->, PO3<2->, COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17<3>, 13<3>, and 3<2> of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis. 1. A bacteriochlorophyll derivative containing at least one negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH , excluding pentacyclic bacteriochlorophyll derivatives having a free CHCHCOOH or a CHCHCOO group at position 17 , and tetracyclic bacteriochlorophyll derivatives devoid of a central metal atom and having a —CHCHCOOH group at position 17 , a —CHCOOH or —COOH group at position 15 , a —COOH group at position 13 , methyl groups at the positions 2 , 7 , 12 , 18 , and ethyl groups at the positions 3 and 8.2. A bacteriochlorophyll derivative according to containing two negatively charged groups.3. A bacteriochlorophyll derivative according to containing three negatively charged groups.4. A bacteriochlorophyll derivative according to wherein said negatively charged groups are selected from the group consisting of COO claim 1 , COS claim 1 , SO claim 1 , and/or PO.5. A bacteriochlorophyll derivative according to wherein said acidic groups that are converted to negatively charged groups at the physiological pH are selected from the group consisting of COOH claim 1 , COSH claim 1 , SOH claim 1 , and/or POH.6. A bacteriochlorophyll derivative according to derived from a natural or synthetic derivative of bacteriochlorophyll claim 1 , including compounds in which the central Mg atom has been deleted or replaced by other metal atoms.8. (canceled)9. ( ...

Подробнее
18-08-2016 дата публикации

MRI CONTRAST AGENTS FOR CELL LABELING

Номер: US20160235866A1
Принадлежит:

Porphyrin compounds useful in the field of magnetic resonance imaging (MRI) as contrast agents. The compounds are relatively lipophilic porphyrins, include one or more enzyme-reactive functional groups, and are cell membrane permeable. Relatively lipophilic group(s) can be enzymatically released within a cell to produce a relatively hydrophilic porphyrin compound. 1. A compound in the form of a metallized paramagnetic tetrapyrollic contrast agent linked to a substituent , wherein the substituent is hydrolysable by an enzyme to form a relatively polar group.2. The compound of claim 1 , wherein the hydrolysable substituent contains a hydrolysable covalent linkage selected from the group consisting of ester (—C(O)O—) claim 1 , ether (—O—) claim 1 , amide (—C(O)NH—) claim 1 , alkylamide (—C(O)NR—) claim 1 , phosphoryl (—OP(O)(OH)O—) claim 1 , alkylphosphoryl (—OP(O)(OR)O—) claim 1 , phosphonyl (—P(O)(OH)O—) claim 1 , alkylphosphonyl (—P(O)(OR)O—) claim 1 , sulfonyl (—S(O)(OH)O—) claim 1 , and alkylsulfonyl (—S(O)(OR)O—) claim 1 , wherein R is (C1-C20) alkyl group claim 1 , branched or unbranched claim 1 , and optionally substituted with one or more of halogen claim 1 , and including salt forms of the phosphoryl claim 1 , phosphonyl claim 1 , sulfuryl and sulfonyl linkage.3. The compound of claim 1 , wherein the enzyme is an esterase.15. The compound of claim 1 , wherein the paramagnetic metal is selected from the group consisting of Mn(II) claim 1 , Mn(III) claim 1 , Fe(II) claim 1 , Fe(III) claim 1 , Gd(III) claim 1 , Cu(I) claim 1 , Cu(II) claim 1 , Ni(II) claim 1 , Ni(I) and Ni(III) claim 1 , wherein the metal in each ring of a said compound may be the same or different.16. The pharmaceutical composition of suitable for administration as an imaging enhancing agent and the contrast agent is present in an amount sufficient to enhance a magnetic resonance image.17. (canceled)18. A method of enhancing an image of a cell claim 23 , the method comprising:exposing the cell ...

Подробнее
16-07-2020 дата публикации

PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY

Номер: US20200223879A1
Принадлежит:

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X. 7. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis phenyl.8. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis substituted phenyl.9. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X).10. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis independently substituted or unsubstituted phenyl , methyl , ethyl , or propyl.11. The pentaaza macrocylic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis methyl , and each Xis hydrogen , hydroxyl , amino , or together with Xis (═O).12. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis substituted or unsubstituted phenyl , and each Xis hydrogen , hydroxyl , methyl , amino , or together with Xis (═O).13. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis hydrogen , hydroxyl , methyl , ethyl , propyl , or amino , or together with Xis (═O).14. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis hydrogen , hydroxyl , methyl , ethyl , propyl , or amino.15. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis methyl or substituted or unsubstituted phenyl and each Xand Xis hydrogen.16. The pentaaza macrocyclic ring complex of any of to wherein each Xis —C(X)(X)(X) and each Xis amino.17. The pentaaza macrocyclic ring complex of any of to and wherein each Xis —C(X)(X)(X) and each Xis —NH.18. The pentaaza macrocyclic ring complex of any of to wherein each Xis —C(X)(X ...

Подробнее
06-11-2014 дата публикации

Catalysts

Номер: US20140329665A1
Принадлежит: Individual

The present invention concerns the synthesis of dry powdered manganese complexes using spray-drying or freeze-drying methods.

Подробнее
06-11-2014 дата публикации

SYNTHETIC CATALASE/SUPEROXIDE DISMUTASE MIMETICS AND METHODS FOR TREATING VIRAL INFECTIONS

Номер: US20140329792A1
Принадлежит:

The invention provides for the treatment of disorders related to viral infection, using salen manganese compounds. 3. The method of claim 2 , wherein the compound suppresses oxidative stress to thereby treat viral infection.5. (canceled)6. The method of claim 1 , wherein the disease or disorder is influenza claim 1 , pandemic influenza virus claim 1 , a retrovirus claim 1 , rhabdovirus claim 1 , filovirus claim 1 , hepatitis type A claim 1 , hepatitis type B claim 1 , hepatitis type C claim 1 , varicella claim 1 , adenovirus claim 1 , human herpes virus claim 1 , herpes simplex type I (HSV-I) claim 1 , herpes simplex type II (HSV-II) claim 1 , rinderpest claim 1 , rhinovirus claim 1 , echovirus claim 1 , rotavirus claim 1 , respiratory syncytial virus claim 1 , papilloma virus claim 1 , papova virus claim 1 , cytomegalovirus claim 1 , echinovirus claim 1 , arbovirus claim 1 , hantavirus claim 1 , coxsachie virus claim 1 , mumps virus claim 1 , measles virus claim 1 , rubella virus claim 1 , polio virus claim 1 , human immunodeficiency virus type I (HIV-I) claim 1 , and human immunodeficiency virus type II (HIV-II) claim 1 , any picornaviridae claim 1 , enteroviruses claim 1 , caliciviridae claim 1 , a Norwalk group of viruses claim 1 , togaviruses claim 1 , alphaviruses claim 1 , flaviviruses claim 1 , Dengue virus claim 1 , coronaviruses claim 1 , rabies virus claim 1 , Marburg viruses claim 1 , Ebola viruses claim 1 , parainfluenza virus claim 1 , orthomyxoviruses claim 1 , bunyaviruses claim 1 , arenaviruses claim 1 , reoviruses claim 1 , rotaviruses claim 1 , orbiviruses claim 1 , human T cell leukemia virus type I claim 1 , human T cell leukemia virus type II claim 1 , simian immunodeficiency virus claim 1 , lentiviruses claim 1 , polyomaviruses claim 1 , parvoviruses claim 1 , Epstein-Barr virus claim 1 , human herpesvirus-6 claim 1 , cercopithecine herpes virus 1 (B virus) claim 1 , varicella zoster virus claim 1 , orthopox virus claim 1 , West Nile Virus ...

Подробнее
23-08-2018 дата публикации

PENTAAZA MACROCYCLIC RING COMPLEXES POSSESSING ORAL BIOAVAILABILITY

Номер: US20180237462A1
Принадлежит:

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X. 7. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis phenyl.8. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis substituted phenyl.9. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X).10. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis independently substituted or unsubstituted phenyl , methyl , ethyl , or propyl.11. The pentaaza macrocylic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis methyl , and each Xis hydrogen , hydroxyl , amino , or together with Xis (═O).12. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis substituted or unsubstituted phenyl , and each Xis hydrogen , hydroxyl , methyl , amino , or together with Xis (═O).13. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis hydrogen , hydroxyl , methyl , ethyl , propyl , or amino , or together with Xis (═O).14. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) and each Xis hydrogen , hydroxyl , methyl , ethyl , propyl , or amino.15. The pentaaza macrocyclic ring complex of any preceding claim wherein each Xis —C(X)(X)(X) , each Xis methyl or substituted or unsubstituted phenyl and each Xand Xis hydrogen.16. The pentaaza macrocyclic ring complex of any of to wherein each Xis —C(X)(X)(X) and each Xis amino.17. The pentaaza macrocyclic ring complex of any of to and wherein each Xis —C(X)(X)(X) and each Xis —NH.18. The pentaaza macrocyclic ring complex of any of to wherein each Xis —C(X)(X ...

Подробнее
01-08-2019 дата публикации

CHELATE COMPOUNDS

Номер: US20190233450A1
Принадлежит:

The invention provides compounds suitable for use as contrast agents in magnetic resonance imaging (MRI). The compounds of the present invention are manganese (II) complexes having advantageous properties as compared with similar known compounds. 2. The compound as defined in claim 1 , wherein each Ris Chydroxyalkyl.3. The compound as defined in claim 1 , wherein each Ris Chydroxyalkyl.4. The compound as defined in claim 1 , wherein each Ris Chydroxyalkyl.7. The compound as defined in claim 1 , wherein each Ris a Caryl substituted with one or more substituents selected from halo or —C(═O)—NH—Chydroxyalkyl.8. The compound as defined in claim 7 , wherein said Caryl is phenyl.9. The compound as defined in claim 7 , wherein said halo is iodo.10. The compound as defined in claim 7 , wherein said —C(═O)—NH—Chydroxyalkyl is —C(═O)—NH—CH—C(OH)—CH—C(OH).13. The compound as defined in claim 1 , wherein each Ris the same.14. The compound as defined in claim 1 , wherein each Ris Calkyl.15. The compound as defined in claim 14 , wherein each Ris methyl.16. The compound as defined in claim 1 , wherein each Ris hydrogen.17. The compound as defined in claim 1 , wherein each Ris Chydroxyalkyl.18. The compound as defined in claim 17 , wherein each Ris Chydroxyalkyl.19. The compound as defined in claim 18 , wherein each Ris Chydroxyalkyl.20. The compound as defined in claim 1 , wherein each Ris the same.21. The compound as defined in claim 1 , wherein each n is an integer from 1-3.22. The compound as defined in claim 21 , wherein each n is 1.23. The compound as defined in claim 21 , wherein each n is 2.24. The compound as defined in claim 21 , wherein each n is 3.25. The compound as defined in claim 1 , wherein Ris Calkyl.26. The compound as defined in claim 25 , wherein Ris methyl.27. The compound as defined in claim 1 , wherein Ris —(CH)—C(═O)—NRR.28. The compound as defined in wherein each Ris Chydroxyalkyl.29. The compound as defined in claim 27 , wherein each Ris is Chydroxyalkyl. ...

Подробнее
23-07-2020 дата публикации

Aminoiodosilanes and methods of synthesizing these aminoiodosilanes

Номер: US20200231616A1
Принадлежит: Entegris Inc

Methods of synthesizing aminoiodosilanes are disclosed. The reaction to produce the disclosed aminoiodosilanes is represented by the formula: SiI 4 +z (NH 2 R 1 )═SiI y (NHR 1 ) z , wherein R 1 is selected from a C 1 -C 10 alkyl or cycloalkyl, aryl, or a hetero group; y=1 to 3; and z=4−y.

Подробнее
17-09-2015 дата публикации

Low-temperature route for precision synthesis of metal oxide nanoparticles

Номер: US20150259217A1
Принадлежит: University of Oregon

Methods for making metal oxide nanoparticles, including mixed metal oxides and core-shell metal oxide nanoparticles, are disclosed. A solution comprising a metal carboxylate and a carboxylic acid is combined with a solvent comprising an alcohol heated to a temperature ≦250° C. for an effective period of time to form metal oxide nanoparticles. The metal may be a group IIIA metal, a group IVA metal, a transition metal, or a combination thereof. A metal oxide shell may be deposited onto metal oxide nanoparticles by dispersing the metal oxide nanoparticles in an alcohol, adding a metal carboxylate, and maintaining the reaction at a temperature ≦200° C. for an effective period of time to form core-shell nanoparticles. The nanoparticles may have a relative size dispersity of ≦20%, and may further comprise a plurality of carboxylic acid, carboxylate, and/or alcohol ligands coordinated to the nanoparticles' outer surfaces.

Подробнее
06-09-2018 дата публикации

THIOCYANATE SALTS FOR ANTI-INFLAMMATION

Номер: US20180251483A1
Автор: Day Brian J., McManus John
Принадлежит:

Described herein, inter alia, are thiocyanate salt compositions and methods for treating or preventing inflammation using the same. 2. The salt of claim 1 , wherein the metal is selected from the group consisting of manganese claim 1 , iron claim 1 , cobalt claim 1 , copper claim 1 , nickel claim 1 , and zinc.3. (canceled)5. The salt of claim 4 , wherein Ris C-Calkyl.7. The salt of claim 6 , wherein Ris C-Calkyl and Rand Rare each unsubstituted ethyl.8. (canceled)9. The salt of claim 8 , wherein A is hydrogen.12. (canceled)13. (canceled)14. The salt as in claim 11 , wherein Xis R-substituted or unsubstituted alkyl;{'sup': 13', '14', '14', '14', '14', '14, 'sub': 2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '3, 'Ris halogen, —NH, —CF, —CHF, —CHF, —CN, —SOCl, —SH, —SONH, —NHNH, —ONH, —NHC(O)NHNH, —NHC(O)N H, —NO, —C(O)H, —C(O)OH, —C(O)NH, —OH, —NHSOH, —NHC (O)H, —NHC(O)OH, —NHOH, —OCF, oxo, —N, R-substituted or unsubstituted heteroalkyl, R-substituted or unsubstituted cycloalkyl, R-substituted or unsubstituted heterocycloalkyl, R-substituted or unsubstituted aryl, or an R-substituted or unsubstituted heteroaryl; and'}{'sup': '14', 'sub': 2', '3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '3', '3, 'Ris halogen, —NH, —CF, —CHF, —CHF, —CN, —SOCl, —SH, —SONH, —NHNH, —ONH, —NHC(O)NHNH, —NHC(O)N H, —NO, —C(O)H, —C(O)OH, —C(O)NH, —OH, —NHSOH, —NHC(O)H, —NHC(O)OH, —NHOH, —OCF, oxo, —N, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, unsubstituted aryl, or unsubstituted heteroaryl.'}15. The salt of claim 14 , wherein Ris C-Calkyl.16. The salt as in claim 11 , wherein Xis Calkyl.17. The salt of claim 16 , wherein A is hydrogen.18. A pharmaceutical composition comprising a salt of and a pharmaceutically acceptable excipient.19. A method of treating inflammation in a subject in need thereof claim 1 , comprising administering to said subject an effective amount of a salt of .20 ...

Подробнее
27-11-2014 дата публикации

IRON AND MANGANESE COMPLEXES COMPRISING HEXADENTATE MONOCARBOXYLATO-CONTAINING LIGANDS AND THEIR USE FOR THE CATALYSIS OF OXIDATION REACTIONS

Номер: US20140350256A1
Автор: MCKENZIE Christine
Принадлежит: UNIVERSITY OF SOUTHERN DENMARK

The present invention relates to iron and manganese complexes based on hexadentate ligand systems containing one carboxylato donor and five nitrogen donor atoms and to their use in methods for the catalysis of the oxidation of organic substrates. The manganese complexes of the invention also may be used as (pro)-catalysts in methods for the catalysis of water. 1. An iron or manganese complex having general formula (I) , (II) or (III):{'br': None, 'sub': 2', '2', 'q', '2', '2', 'q, 'sup': z', 'z, '[(LH)Fe(O)]Yor [(L)Fe(O)]Y\u2003\u2003(I)'}{'br': None, 'sup': 'z', 'sub': 'q', '[LM]Y\u2003\u2003(II)'}{'br': None, 'sup': 'z', 'sub': 'q', '[LM(X)]Y\u2003\u2003(III)'}wherein:M represents a metal ion selected from Fe or Mn in the II, III, IV or V oxidation state; {'br': None, 'sup': 1', '1', '1', '−, 'RRN-A-N(R)WC(O)O\u2003\u2003(IV)'}, 'L represents a monoanionic potentially hexadentate ligand containing one carboxylate group and five nitrogen donor atoms, wherein the ligand coordinates to the Fe or Mn metal ion in the complex via said carboxylate group and at least four of said nitrogen donor atoms and has general formula (IV)wherein:{'sup': 1', '2', '2, 'each Rindependently represents —R—B, in which Rrepresents an optionally substituted group selected from the group consisting of alkylene, alkenylene, oxyalkylene, aminoalkylene and alkylene ether, and B represents an optionally substituted heteroaryl group selected from the group consisting of pyridinyl, pyrazinyl, pyrazolyl, imidazolyl, benzimidazolyl, pyrimidinyl, triazolyl and thiazolyl;'}{'sub': 2', '2', '2', '2', '2', '10', '6', '4, 'A represents an optionally substituted alkylene or arylene bridging group selected from the group consisting of —CHCH—, —CHCHCH—, —CH—, and —CH; and'}W represents a group selected from the group consisting of alkylene, arylene and arylalkylene;{'sub': 2', '3', '2', '4, 'sup': −', '−', '−', '−', '−', '−', '−', '2−', '−', '−', '−, 'X represents a coordinating species selected from the ...

Подробнее
22-09-2016 дата публикации

METAL COMPLEXES CONTAINING AMIDOIMINE LIGANDS

Номер: US20160273106A1
Принадлежит:

Metal complexes containing one or more amidoimine ligands, methods of making such metal complexes, and methods of using such metal complexes to prepare metal-containing films are provided. 2. The metal complex of claim 1 , wherein M is selected from the group consisting of manganese claim 1 , cobalt claim 1 , nickel claim 1 , and copper; and R claim 1 , R claim 1 , R claim 1 , and Rare independently selected from the group consisting of C-C-alkyl and C-C-aryl.3. (canceled)4. (canceled)5. The metal complex of claim 1 , wherein Rand R are each methyl.6. (canceled)7. The metal complex of claim 1 , wherein L comprises an amidoimine ligand claim 1 , a diazabutadiene ligand claim 1 , an amidinate ligand claim 1 , or an allyl ligand.8. The metal complex of claim 1 , wherein L comprises an η-allyl ligand.10. The metal complex of claim 9 , wherein M is selected from the group consisting of manganese claim 9 , cobalt claim 9 , nickel claim 9 , and copper; and R claim 9 , R claim 9 , R claim 9 , R claim 9 , R claim 9 , R claim 9 , Rand R are independently selected from the group consisting of C-C-alkyl and C-C-aryl.11. (canceled)12. (canceled)13. The metal complex of claim 9 , wherein R claim 9 , R claim 9 , R claim 9 , and R are each methyl.14. (canceled)16. The metal complex of claim 15 , wherein M is selected from the group consisting of manganese claim 15 , cobalt claim 15 , nickel claim 15 , and copper; and wherein R claim 15 , R claim 15 , R and Rare independently selected from the group consisting of C-C-alkyl and C-C-aryl; and R claim 15 , R claim 15 , R claim 15 , and Rare independently selected from the group consisting of hydrogen claim 15 , C-C-alkyl claim 15 , and C-C-aryl.17. (canceled)18. (canceled)19. The metal complex of claim 15 , wherein Rand R are each methyl and Rand Rare each hydrogen.20. (canceled)22. The metal complex of claim 21 , wherein M is selected from the group consisting of manganese claim 21 , cobalt claim 21 , nickel claim 21 , and copper; and ...

Подробнее
22-08-2019 дата публикации

Lead-free initiating agents or initiating agent mixtures

Номер: US20190256438A1
Принадлежит: DynITEC GmbH

Subject matter of the invention are lead-free initiating agents or initiating agent mixtures and initiating and igniting compositions which contain the lead-free initiating agents or initiating agent mixtures

Подробнее
22-08-2019 дата публикации

Nitrogen-Containing Ligands And Their Use In Atomic Layer Deposition Methods

Номер: US20190256467A1
Принадлежит:

Methods for deposition of elemental metal films on surfaces using metal coordination complexes comprising nitrogen-containing ligands are provided. Also provided are nitrogen-containing ligands useful in the methods of the invention and metal coordination complexes comprising these ligands. 1. A metal coordinating ligand having a formula{'sub': 1', '2', 'x', 'y', '7', '8', '1-6', '2-4', '1', '2', '7', '8', '3', '4', '5', '6, 'a) RRN—(CR)—N—(CR)—NRR, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl and x and y are independently 2-6, provided that when each of R, R, Rand Ris ethyl, at least one of R, R, Rand Ris not H;'}{'sub': Ar1', '1', '2', 'x', '5', '3', 'y', 'Ar2', '1-6', '2-4', 'Ar1', 'Ar2, 'b) N—(CRR)—NR—(CRR)—N, wherein each R is independently hydrogen, Calkyl, acyl, aldehyde, keto or Calkenyl, and Nand Nmay be the same or different and are heterocyclic aromatic moieties wherein the heteroatom is N.'}3. The metal coordinating ligand of claim 2 , wherein R claim 2 , R claim 2 , Rand Rof formula I are each ethyl (Et) and each of R-Ris independently hydrogen claim 2 , Calkyl claim 2 , acyl claim 2 , aldehyde claim 2 , keto or Calkenyl.4. A metal coordination complex comprising a transition metal ion or a boron group ion M complexed with the metal coordinating ligand of .8. The metal coordination complex of claim 7 , wherein L is one or more of halogen claim 7 , alkyl claim 7 , amino and methylamino.9. The metal coordination complex of claim 7 , wherein L is an NNN ligand.10. The metal coordination complex of claim 4 , wherein the transition metal ion or the boron group ion is selected from the group consisting of aluminum claim 4 , titanium claim 4 , tungsten claim 4 , zirconium claim 4 , vanadium claim 4 , niobium claim 4 , tantalum claim 4 , chromium claim 4 , molybdenum claim 4 , palladium claim 4 , platinum claim 4 , rhodium claim 4 , iridium claim 4 , silver claim 4 , gold claim 4 , hafnium claim 4 , manganese claim 4 , ...

Подробнее
20-09-2018 дата публикации

THERMALLY STABLE VOLATILE PRECURSORS

Номер: US20180265975A1
Принадлежит:

A method of forming a thin film on a substrate which includes a step of contacting a surface with a precursor compound having a transition metal and one or more alkyl-1,3-diazabutadiene ligands is provided. The resulting modified surface is then contacted with an activating compound. 2. The method of wherein the activating compound is a reducing agent and the thin film is a metallic film.3. The method of wherein the reducing agent is selected from the group consisting of molecular hydrogen claim 2 , atomic hydrogen claim 2 , silane claim 2 , disilane claim 2 , organosilanes claim 2 , compounds containing Si—H bonds claim 2 , germane claim 2 , organogermanes claim 2 , compounds containing Ge—H bonds claim 2 , stannane claim 2 , compounds containing Sn—H bonds claim 2 , other metal hydride compounds claim 2 , formic acid claim 2 , glyoxalic acid claim 2 , oxalic acid claim 2 , other carboxylic acids claim 2 , diborane claim 2 , compounds containing B—H bonds claim 2 , hydrazine claim 2 , carbon-substituted hydrazines claim 2 , formalin claim 2 , formaldehyde claim 2 , organic alcohols claim 2 , organoaluminum compounds claim 2 , organozinc compounds claim 2 , and plasma-activated versions thereof.4. The method of wherein the activating compound is an oxidizing agent and the thin film is a metal oxide.5. The method of wherein the oxidizing agent is selected from the group consisting of water claim 4 , ozone claim 4 , molecular oxygen claim 4 , atomic oxygen claim 4 , organic alcohols claim 4 , hydrogen peroxide claim 4 , organic hydroperoxides claim 4 , organic peroxides claim 4 , nitrous oxide claim 4 , and plasma-activated versions of thereof.6. The method of wherein the activating compound is a nitrogen-containing agent and the thin film is a metal nitride.7. The method of wherein the nitrogen activating compound is selected from the group consisting of ammonia claim 6 , hydrazine claim 6 , alkyl-substituted hydrazines claim 6 , and plasma activated versions thereof ...

Подробнее
28-09-2017 дата публикации

PURE CHELATION PROCESS

Номер: US20170274370A1
Принадлежит:

The present invention relates to metal complexes and methods of synthesizing the metal complexes. The invention is further directed to pharmaceutical and/or dietary supplement composition comprising compounds synthesized as described herein. 1. A method of synthesizing chelated metals , comprising the steps of:dissociating a metal salt in water to produce an aqueous solution of metal ions;solubilizing a chelating agent in water to produce an aqueous solution of chelating agent;mixing the aqueous solution of metal ions with the aqueous solution of chelating agent to produce an aqueous solution containing a metal chelate; andprecipitating a metal chelate product out of the aqueous solution containing a metal chelate by adjusting the pH to between about 3 and about 4,wherein the method is conducted in an oxygen-free environment.2. The method of claim 1 , further comprising the steps of:cooling the aqueous solution containing metal chelate;collecting the metal chelate product from the aqueous solution containing a metal chelate; andwashing the metal chelate product with ascorbic acid followed by absolute alcohol.3. The method of claim 1 , wherein the metal salt is the salt of a transition metal.4. The method of claim 3 , wherein the transition metal is a member of the group 7 transition metals.5. The method of claim 3 , wherein the transition metal is selected from the group consisting of: copper claim 3 , cobalt claim 3 , nickel claim 3 , zinc claim 3 , and manganese.6. The method of claim 1 , wherein the steps of dissociating a metal salt in water is performed in a first nitrogen-purged reactor.7. The method of claim 1 , wherein the step of dissociating the metal salt in water further comprises the step of mixing the metal with hydrochloric acid.8. The method of claim 1 , wherein the metal salt is completely dissolved during the step of dissociating the metal salt in water.9. The method of claim 8 , wherein the step of dissociating the metal salt in water comprises ...

Подробнее
28-09-2017 дата публикации

First-Row Transition Metal Hydrogenation and Hydrosilylation Catalysts

Номер: US20170275321A1
Принадлежит:

Transition metal compounds, and specifically transition metal compounds having a tetradentate and/or pentadentate supporting ligand are described, together with methods for the preparation thereof and the use of such compounds as hydrogenation and/or hydrosilylation catalysts. 4. The metal complex of claim 1 , wherein:M is Mn, Fe, Co, or Ni; and{'sub': 2', '2, 'each X is independently selected from PR, NR, and any other donor group.'}5. The metal complex of claim 3 , wherein Z is hydride.6. A catalytic composition comprising the metal complex of .7. A method for reducing one or more organic substrates comprising contacting a composition comprising one or more organic substrates with a catalytic composition comprising a metal complex according to in the presence of a reductant claim 1 , whereby the one or more organic substrates are reduced.8. The method of claim 8 , wherein the reductant is a silane claim 8 , a substituted silane claim 8 , an alkoxysilane claim 8 , hydrogen claim 8 , a substituted borane claim 8 , a substituted alane claim 8 , or a mixture thereof.9. The method of claim 7 , wherein the one or more organic substrates contain a ketone claim 7 , an ester claim 7 , or mixtures thereof.10. The method of claim 9 , wherein the one or more organic substrates include an unsaturated organic compound.11. The method of claim 10 , wherein the unsaturated organic compound is an olefin or an alkyne.12. A method of facilitating a hydrosilylation reaction claim 1 , comprising reacting a compound comprising an Si—H bond with an unsaturated organic compound in the presence of one or more of the metal complexes of .13. The method of claim 12 , whereby the Si and H atoms in the Si—H bond are added across an unsaturated bond in the unsaturated organic compound to form an organosilicon compound.14. A method of facilitating a hydrogenation reaction claim 1 , comprising reacting Hwith an unsaturated organic compound in the presence of one or more of the metal complexes of . ...

Подробнее